Origin Materials (ORGN) 10-Q 9 Aug 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2023	Aug. 04, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-39378
Entity Registrant Name	ORIGIN MATERIALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-1388928
Entity Address, Address Line One	930 Riverside Parkway
Entity Address, Address Line Two	Suite 10
Entity Address, City or Town	West Sacramento,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95605
City Area Code	916
Local Phone Number	231-9329
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ORGN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		143,515,614
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001802457
Warrant
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	ORGNW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 65,523	$ 107,858
Restricted cash	490	490
Marketable securities	152,170	215,464
Accounts receivable	7,280	0
Other receivables	6,815	4,346
Inventory	346	0
Derivative asset	160	0
Prepaid expenses and other current assets	3,268	3,341
Total current assets	236,052	331,499
Property, plant, and equipment, net	220,807	154,183
Operating lease right-of-use asset	2,479	2,779
Intangible assets, net	142	160
Other long-term assets	17,224	5,079
Total assets	476,704	493,700
Current liabilities
Accounts payable	6,755	10,384
Accrued expenses	4,355	8,414
Operating lease liability, current	611	619
Other liabilities, current	397	51
Derivative liability	9	344
Total current liabilities	12,127	19,812
Earnout liability	22,386	42,533
Canadian Government Research and Development Program liability	7,345	7,185
Assumed common stock warrants liability	26,249	30,872
Notes payable	5,189	5,847
Operating lease liability	1,962	2,249
Other liabilities, long-term	8,943	8,297
Total liabilities	84,201	116,795
Commitments and contingencies (See Note 19)
STOCKHOLDERS’ EQUITY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of June 30, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value, 1,000,000,000 shares authorized; 143,498,724 and 143,034,225, issued and outstanding as of June 30, 2023 and December 31, 2022, respectively (including 4,500,000 Sponsor Vesting Shares)	14	14
Additional paid-in capital	377,059	371,072
Retained earnings	25,077	21,772
Accumulated other comprehensive loss	(9,647)	(15,953)
Total stockholders’ equity	392,503	376,905
Total liabilities and stockholders’ equity	$ 476,704	$ 493,700

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	143,498,724	143,034,225
Common stock, shares outstanding (in shares)	143,498,724	143,034,225
Sponsor vesting shares issued (in shares)	4,500,000	4,500,000
Sponsor vesting shares outstanding (in shares)	4,500,000	4,500,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues	$ 6,898,000	$ 0	$ 8,602,000	$ 0
Cost of revenues (exclusive of depreciation and amortization shown separately below)	6,814,000	0	7,774,000	0
Operating expenses
Research and development	5,396,000	2,649,000	10,471,000	4,985,000
General and administrative	8,619,000	5,864,000	16,275,000	10,935,000
Depreciation and amortization	347,000	160,000	635,000	308,000
Total operating expenses	14,362,000	8,673,000	27,381,000	16,228,000
Loss from operations	(14,278,000)	(8,673,000)	(26,553,000)	(16,228,000)
Other income (expenses)
Interest income	2,426,000	1,936,000	5,440,000	3,768,000
Interest expenses	(2,000)	0	(2,000)	0
Gain (loss) in fair value of derivatives	(266,000)	1,430,000	494,000	596,000
Gain (loss) in fair value of warrants liability	(2,143,000)	18,803,000	4,623,000	17,029,000
Gain in fair value of earnout liability	7,508,000	33,188,000	20,380,000	48,414,000
Other income (expenses), net	420,000	247,000	(948,000)	698,000
Total other income, net	7,943,000	55,604,000	29,987,000	70,505,000
Net income (loss) before income tax expenses	(6,335,000)	46,931,000	3,434,000	54,277,000
Income tax expenses	(129,000)	0	(129,000)	0
Net Income (Loss) Attributable to Parent, Total	(6,464,000)	46,931,000	3,305,000	54,277,000
Other comprehensive income (loss)
Unrealized gain (loss) on marketable securities, net of tax	1,504,000	(4,805,000)	2,914,000	(9,380,000)
Foreign currency translation adjustment, net of tax	3,272,000	(1,693,000)	3,392,000	(808,000)
Total comprehensive income (loss)	$ (1,688,000)	$ 40,433,000	$ 9,611,000	$ 44,089,000
Net income (loss) per share, basic (in dollars per share)	$ (0.05)	$ 0.34	$ 0.02	$ 0.40
Net income (loss) per share, diluted (in dollars per share)	$ (0.05)	$ 0.33	$ 0.02	$ 0.38
Weighted-average common shares outstanding, basic (in shares)	139,265,248	137,141,655	139,154,557	136,985,440
Weighted-average common shares outstanding, diluted (in shares)	139,265,248	142,195,637	143,039,435	142,078,752

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity and Accumulated Other Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive loss
Balance beginning (in shares) at Dec. 31, 2021		141,301,569
Balance beginning at Dec. 31, 2021	$ 303,510	$ 16	$ 361,542	$ (56,797)	$ (1,251)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options (in shares)		944,716
Common stock issued upon exercise of stock options	268	$ (2)	270
Vested common stock awards (in shares)		132,649
Stock-based compensation	3,041		3,041
Net income (loss)	54,277			54,277
Other Comprehensive (loss) income	(10,188)				(10,188)
Ending balance at Jun. 30, 2022	350,908	$ 14	364,853	(2,520)	(11,439)
Ending balance (in shares) at Jun. 30, 2022		142,378,934
Balance beginning (in shares) at Mar. 31, 2022		141,418,989
Balance beginning at Mar. 31, 2022	308,394	$ 16	362,770	(49,451)	(4,941)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options (in shares)		827,296
Common stock issued upon exercise of stock options	234	$ (2)	236
Vested common stock awards (in shares)		132,649
Stock-based compensation	1,847		1,847
Net income (loss)	46,931			46,931
Other Comprehensive (loss) income	(6,498)				(6,498)
Ending balance at Jun. 30, 2022	350,908	$ 14	364,853	(2,520)	(11,439)
Ending balance (in shares) at Jun. 30, 2022		142,378,934
Balance beginning (in shares) at Dec. 31, 2022		143,034,225
Balance beginning at Dec. 31, 2022	376,905	$ 14	371,072	21,772	(15,953)
Ending balance at Mar. 31, 2023	391,142	$ 14	374,010	31,541	(14,423)
Ending balance (in shares) at Mar. 31, 2023		143,267,991
Balance beginning (in shares) at Dec. 31, 2022		143,034,225
Balance beginning at Dec. 31, 2022	376,905	$ 14	371,072	21,772	(15,953)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options (in shares)		371,903
Common stock issued upon exercise of stock options	54		54
Vested common stock awards (in shares)		92,596
Stock-based compensation	5,933		5,933
Net income (loss)	3,305			3,305
Other Comprehensive (loss) income	6,306				6,306
Ending balance at Jun. 30, 2023	392,503	$ 14	377,059	25,077	(9,647)
Ending balance (in shares) at Jun. 30, 2023		143,498,724
Balance beginning (in shares) at Mar. 31, 2023		143,267,991
Balance beginning at Mar. 31, 2023	391,142	$ 14	374,010	31,541	(14,423)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options (in shares)		208,807
Common stock issued upon exercise of stock options	31		31
Vested common stock awards (in shares)		21,926
Stock-based compensation	3,018		3,018
Net income (loss)	(6,464)			(6,464)
Other Comprehensive (loss) income	4,776				4,776
Ending balance at Jun. 30, 2023	$ 392,503	$ 14	$ 377,059	$ 25,077	$ (9,647)
Ending balance (in shares) at Jun. 30, 2023		143,498,724

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net Income (Loss)	$ 3,305	$ 54,277
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	635	308
Amortization on right-of-use asset	301	281
Stock-based compensation	4,651	2,573
Realized loss of marketable securities	706	0
Amortization premium of marketable securities	285	0
Gain (loss) in fair value of derivatives	(494)	(596)
Change in fair value of common stock warrants liability	(4,623)	(17,029)
Gain in fair value of earnout liability	(20,380)	(48,414)
Change in fair value of incremental acquisition fee accrual	0	(150)
Changes in operating assets and liabilities:
Receivables	(9,748)	(377)
Inventory	(346)	0
Prepaid expenses and other current assets	72	1,038
Other long-term assets	(12,144)	0
Accounts payable	2,111	2,157
Accrued expenses	49	2,476
Operating lease liability	(354)	(193)
Other liabilities, current	347	489
Other liabilities, long-term	(7)	128
Net cash used in operating activities	(35,634)	(3,032)
Cash flows from investing activities
Purchases of property, plant, and equipment, net of grants	(72,284)	(25,045)
Purchases of marketable securities	(2,499,506)	(1,655,200)
Sales of marketable securities	2,462,950	1,647,787
Maturities of marketable securities	101,792	71,168
Capitalized interest on plant construction	0	(47)
Net cash (used in) provided by investing activities	(7,048)	38,663
Cash flows from financing activities
Proceeds from exercise of stock options	55	268
Net cash provided by financing activities	55	268
Effects of foreign exchange rate changes on the balance of cash and cash equivalents, and restricted cash held in foreign currencies	292	(3,480)
Net (decrease) increase in cash and cash equivalents, and restricted cash	(42,335)	32,419
Cash and cash equivalents, and restricted cash, beginning of the period	108,348	47,127
Cash and cash equivalents, and restricted cash, end of the period	66,013	79,546
Supplemental disclosure for non-cash transactions
Operating lease right-of-use asset obtained in exchange for lease obligations	0	1,710
Stock-based compensation capitalized into property, plant, and equipment	1,282	467
Purchases of property, plant, and equipment included in accounts payable and accrued expenses and capitalized interest	7,474	0
Cash paid during the period:
Income taxes payment	$ 20	$ 0

Organization and Business

Organization and Business	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	Organization and Business Unless the context otherwise requires, references in these notes to “Origin”, “the Company”, “we”, “us” and “our” and any related terms are intended to mean the post-Business Combination Origin Materials, Inc. and its consolidated subsidiaries. The Company’s mission is to help enable the world’s transition to sustainable materials by replacing petroleum-based materials with decarbonized materials in a wide range of end products, such as food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, fuels, and more. The Company’s technology can convert sustainable feedstocks, such as sustainably harvested wood, agricultural waste, wood waste and corrugated cardboard, into materials and products that are currently made from fossil feedstocks, such as petroleum and natural gas. The Company’s products are intended to compete directly with petroleum-derived products on both performance and price, as well as provide a significant unit cost advantage over products made from other low-carbon feedstocks. On June 27, 2023, the Company began startup of its “Origin 1” facility, the world’s first commercial chloromethylfurfural (“CMF”) plant, located in Sarnia, Ontario. The Company is also currently in the planning phase for the construction of “Origin 2,” its significantly larger manufacturing plant. On June 25, 2021 (the “Closing Date”), Artius Acquisition Inc. (“Artius”), a special purpose acquisition company, consummated the Merger Agreement and other Related Agreements (the “Merger Agreement”) dated February 16, 2021, by and among Artius, Zero Carbon Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Artius (“Merger Sub”), and Micromidas, Inc. a Delaware corporation (now known as Origin Materials Operating Inc., (“Legacy Origin”)). Pursuant to the terms of the Merger Agreement, a business combination between Artius and Legacy Origin was effected through the merger of Merger Sub with and into Legacy Origin, with Legacy Origin surviving as the surviving company and as a wholly-owned subsidiary of Artius (the “Merger” and, collectively with the other transactions described in the Merger Agreement, the “Business Combination”). On the Closing Date, Artius changed its name to Origin Materials, Inc. (collectively with its subsidiaries, the “Company”).

Risks and Liquidity

Risks and Liquidity	6 Months Ended
	Jun. 30, 2023
Risks And Liquidity [Abstract]
Risks and Liquidity	Risks and Liquidity The Company believes that its $217.7 million of cash and cash equivalents, and marketable securities as of June 30, 2023 will enable it to fund its planned operations for at least twelve months from the issuance date of these unaudited condensed consolidated financial statements. Over the last several years, our operations have been impacted by the COVID-19 pandemic, inflationary pressures and ongoing geopolitical conflicts. We continue to monitor the impact of any lingering effects of the COVID-19 pandemic on our business, operations and access to supply and raw materials. In February 2022, Russia began a military intervention in Ukraine. In response, global sanctions were imposed against Russia. These sanctions and the related global ramifications could increase the cost of transportation or limit the availability of certain materials of construction, such as metals used in alloys, that are sourced from Russia or Ukraine and used in our manufacturing facilities. Inflation rates continue to have an effect on worldwide economies. Inflationary pressures and any shortages in the labor market could increase labor costs, which could in turn materially impact our financial condition.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The Company’s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). Use of Estimates The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of revenues, costs and expenses during the reporting periods. Estimates made by the Company include, but are not limited to, valuation of the earnout liability, valuation of assumed common stock warrants liability, carrying amount and useful lives of property and equipment and intangible assets, impairment assessments, marketable securities, stock-based compensation expenses, probabilities of achievement of performance conditions on performance stock awards, among others. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Unaudited Interim Condensed Consolidated Financial Statements The accompanying interim Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022, the interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), and the interim Condensed Consolidated Statements of Stockholders’ Equity and Accumulated Other Comprehensive Loss for the three and six months ended June 30, 2023 and 2022, and the interim Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022, and the notes to such interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. As permitted under those rules, we condensed or omitted certain footnotes or other financial information that are normally required by GAAP for annual financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in management’s opinion, include all adjustments consisting of only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2023 and its results of operations for the three and six months ended June 30, 2023 and 2022 and cash flows for the six months ended June 30, 2023 and 2022. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the full fiscal year or any other period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto for the year ended December 31, 2022 included the Company’s Form 10-K as filed with the SEC on February 23, 2023. Principles of Consolidation The unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents, and marketable securities. The Company maintains its cash, cash equivalents, and marketable securities accounts with financial institutions where, at times, deposits exceed federal insurance limits. Management believes that the Company is not currently exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality. While the Company has not experienced losses of these deposits to date, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business could be adversely affected. Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an initial maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains such funds in cash deposits and money market accounts. Restricted cash consists of cash held in a control account as collateral for the Company’s credit card services, escrow services, and standby letter of credit. These restricted cash balances have been excluded from cash and cash equivalents balance in the Unaudited Condensed Consolidated Balance Sheets based on the contractual term. The Company entered into an escrow agreement on September 27, 2019 for $1.3 million, whereby the funds would be used for construction and transportation services in connection with Origin 1. At June 30, 2023 and December 31, 2022, the escrow account had a balance of $0.3 million. The Company has a standby letter of credit, whereby the funds may be used for the completion of work, services, and improvements in connection with Origin 1. The standby letter of credit matures and automatically renews in October of each year. At June 30, 2023 and December 31, 2022, the standby letter of credit was $0.2 million. Cash, cash equivalents, and restricted cash consisted of the following (in thousands): June 30, 2023 December 31, 2022 Cash and cash equivalents $ 65,523 $ 107,858 Restricted cash 490 490 Total cash, cash equivalents, and restricted cash $ 66,013 $ 108,348 Marketable Securities The Company’s investment policy requires the Company to purchase investments that are consistent with the classification of available-for-sale securities. The Company does not buy and hold securities principally for the purpose of selling them in the near future. The Company’s policy is focused on the preservation of capital, liquidity, and return. The Company considers all of its marketable debt securities as available for use in current operations, including those with maturity dates beyond one year, and therefore classifies these securities within current assets on the condensed consolidated balance sheets. Securities are classified as available for sale and are carried at fair value, with the change in unrealized gains and losses, net of tax, reported as a separate component on the condensed consolidated statements of operations and comprehensive income (loss) until realized. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such as quoted prices, interest rates and yield curves. Securities with an amortized cost basis in excess of estimated fair value are assessed to determine what amount of the excess, if any, is caused by expected credit losses. Expected credit losses on securities are recognized in other income (expenses), net on the condensed consolidated statements of operations and comprehensive income (loss), and any remaining unrealized gains and losses, net of taxes, are included in accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ equity and accumulated other comprehensive loss. For the purposes of computing realized and unrealized gains and losses, the cost of securities sold is based on the specific-identification method. Amortization of discounts and premiums, net, and interest on securities classified as available for sale are included as a component of interest income within other income (expenses). The nature of these financial instruments include instruments for which quoted prices are available but traded less frequently, instruments whose fair value has been derived using a model where inputs to the model are directly observable in the market, or can be derived principally from or corroborated by observable market data, and instruments that are fair valued using other financial instruments, the parameters of which can be directly observed. Level 2 financial instruments include agency mortgage-backed securities, corporate fixed income securities infrequently traded, and other securities, which primarily consist of sovereign debt, U.S. government agency securities, loans, and state and municipal securities. Derivative Financial Instruments The Company enters into foreign currency derivative contracts with financial institutions to reduce foreign exchange risk related to marketable securities. The Company uses forward currency derivative contracts to minimize the Company’s exposure to balances primarily denominated in the British Pound Sterling and Australian Dollar. The Company’s foreign currency derivative contracts, which are not designated as hedging instruments, are used to reduce the exchange rate risk associated primarily with marketable securities. The Company’s derivative financial instruments program is not designated for trading or speculative purposes. Outstanding foreign currency derivative contracts are recorded at fair value on the condensed consolidated balance sheets. Foreign currency derivative contracts are marked-to-market at the end of each reporting period with gains and losses recognized in the change in fair value of derivatives within other income (expenses). While the contract or notional amount is often used to express the volume of foreign currency derivative contracts, the amounts potentially subject to credit risk are generally limited to the amounts, if any, by which the counterparties’ obligations under the agreements exceed the obligations of the Com pany to the counterparties. The notional amount of foreign currency derivative contracts as of June 30, 2023 and December 31, 2022 was $16.6 million and $21.2 million, respectively. Fair Value of Financial Instruments The Company applies the fair value measurement accounting standard whenever other accounting pronouncements require or permit fair value measurements. Fair value is defined in the accounting standard as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy under current accounting guidance prioritizes the inputs to valuation techniques used to measure fair value into three broad levels (Level 1, Level 2, and Level 3). Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk) in a principal market. The carrying amounts of working capital balances approximate their fair values due to the short maturity of these items. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest rate, currency, or credit risks arising from its financial instruments. We have determined the fair value of debt approximates the carrying value due to the standard terms of the arrangement including but not limited to the amount borrowed, the term, and the interest rate. The fair values of cash equivalents and the Assumed Common Stock Warrants which are publicly traded are Level 1 inputs. The fair value of the Assumed Common Stock Warrants which are not publicly traded, marketable securities, and foreign currency derivative contracts are Level 2 inputs as the Company uses quoted market prices or alternative pricing sources and models utilizing observable market inputs. The earnout liability was estimated using Level 3 inputs. Accounts Receivable We record accounts receivable at the stated amount of the transactions with our customers, and we do not charge interest. The allowance for credit losses, known as the Current Expected Credit Losses ("CECL") model, is our best estimate of the amount of probable credit losses associated with our accounts receivable. We determine the allowance based on current conditions, and reasonable and supportable forecasts. Past-due balances are reviewed individually for collectability. We charge off account balances against the allowance after we have exhausted all means of collection and we consider the potential for recovery to be remote. Our accounts receivable generally have net 30 to net 90-day payment terms, and we usually receive consideration in accordance with the payment terms of the contract. As of June 30, 2023 , we do not have any allowance for credit losses. Other Receivables Other receivables consist of amounts due from foreign governmental entities related to the Canadian harmonized sales tax (“HST”) and goods and services tax (“GST”) for goods and services transacted in Canada, and amounts due from cash collateral held by others for foreign currency derivative contracts. AgriScience Grant In January 2019, the Company entered into an agreement in which it will participate in the AgriScience Program Cluster Component grant through the Canadian Agricultural Partnership, whereby the Company will receive reimbursements for eligible expenditures up to approximately $1.8 million (in Canadian dollars) incurred through March 2023. Grants are received through reimbursements from the Canadian government and recognized, upon completion of scope of services on a quarterly basis. Grants are recognized as a reduction of property, plant, and equipment or expenses based on the nature of the cost the grant is reimbursing. The Company received $0.1 million during the three and six months ended June 30, 2023, and zero during the three and six months ended June 30, 2022 in grants, recorded in other income (expenses). The Company is not entitled to any further grants under this AgriScience Program. Inventory Inventories are stated at the lower of cost or net realizable value. Cost is determined using a weighted-average cost approach, assuming full absorption of direct and indirect manufacturing costs, or based on cost of purchasing from our vendors. If inventory costs exceed expected net realizable value due to obsolescence or lack of demand, valuation adjustments are recorded for the difference between the cost and the expected net realizable value. Property, Plant, and Equipment Property, plant, and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. Depreciation normally begin when assets are ready for its intended use. Leasehold improvements are amortized using the straight-line method over the shorter of their estimated useful lives or the lease term. Major additions and improvements are capitalized, while replacements, repairs, and maintenance that do not extend the life of an asset are charged to operations. We depreciate plants over a maximum life of 40 years and plant improvements over the shorter of the asset life or remaining useful life of the plants structure using the straight-line method. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts. Costs incurred to acquire, construct or install property, plant, and equipment during the construction stage of a capital project and costs capitalized in conjunction with major improvements that have not yet been placed in service are recorded as construction in progress, and accordingly are not currently being depreciated. The Company capitalizes interest cost incurred on funds used to construct property, plant and equipment. The estimated useful lives of assets are as follows: Computer and other equipment 3 years Pilot plant 5 years Machinery and equipment 5 years Leasehold improvements 1-5 years Plants and improvements 20-40 years Intangible Assets Intangible assets are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the respective assets, ranging from 7 to 15 years. The cost of servicing the Company’s patents is expensed as incurred. Upon retirement or sale, the cost of intangible assets is disposed of and the related accumulated amortization is removed from the accounts. The Company reviews its long-lived assets, including property, equipment, software and intangibles, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. If indicators of impairment exist, management identifies the asset group which includes the potentially impaired long-lived asset, at the lowest level at which there are separate, identifiable cash flows. If the total of the expected undiscounted future net cash flows for the asset group is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. As of June 30, 2023, no impairment was identified. Assumed Common Stock Warrants Liability The Company assumed 24,149,960 public warrants (the “Public Warrants”) and 11,326,667 private placement warrants (the “Private Placement Warrants”, and the Public Warrants together with the Private Placement Warrants, the “Assumed Common Stock Warrants” or “Warrants”) upon the Business Combination, all of which were issued in connection with Artius’ initial public offering and entitle each holder to purchase one share of Class A common stock at an exercise price of at $11.50 per share. As of June 30, 2023, 24,149,960 Public Warrants and 11,326,667 Private Placement Warrants are outstanding. The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the warrants may be cashless exercised. The Private Placement Warrants are transferable, assignable or salable in certain limited exceptions. The Private Placement Warrants are exercisable for cash or on a cashless basis, at the holder’s option, and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will cease to be Private Placement Warrants, and become Public Warrants and be redeemable by the Company and exercisable by such holders on the same basis as the other Public Warrants. The Company evaluated the Assumed Common Stock Warrants under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”) , and concluded they do not meet the criteria to be classified in stockholders’ equity. Specifically, the exercise of the Assumed Common Stock Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves 50% or more of our Class A stockholders. Because not all of the voting stockholders need to participate in such tender offer or exchange to trigger the potential cash settlement and the Company does not control the occurrence of such an event, the Company concluded that the Assumed Common Stock Warrants do not meet the conditions to be classified in equity. Since the Assumed Common Stock Warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as liabilities on the Condensed Consolidated Balance Sheets at fair value, with subsequent changes in their respective fair values recognized in the change in fair value of Assumed Common Stock Warrant liabilities within the Condensed Consolidated Statements of Operations and Comprehensive Income at each reporting date. The Public Warrants were publicly traded and thus had an observable market price to estimate fair value, and the Private Placement Warrants were effectively valued similar to the Public Warrants, as described in Note 6. Earnout Liability The Company has recorded an earnout liability related to future contingent equity shares related to the Business Combination (Note 13). The Company recorded these instruments as liabilities on the Condensed Consolidated Balance Sheets at fair value, with subsequent changes in their respective fair values recognized in earnings at each reporting date. Leases The Company has leases for office space and equipment, some of which have escalating rentals during the initial lease term and during subsequent optional renewal periods. The Company accounts for its leases under ASC 842, Leases . The Company recognizes a right-of-use asset and lease liability for leases based on the net present value of future minimum lease payments. Lease expense is recognized on a straight-line basis over the non-cancelable lease term and renewal periods that are considered reasonably certain to be exercised. Revenue Recognition The Company began to recognize revenue in 2023. Our revenues are from product sales and service agreements. The majority of our contracts with customers typically contain multiple products and services. We account for individual products and services separately if they are distinct-that is, if a product or service is separately identifiable from other items in the contract and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”) . The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or service to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our product revenue and collaborative research and development agreements, we perform the following steps: 1. Identifying the contract with a customer; 2. Identifying the performance obligations in the contract; 3. Determining the transaction price; 4. Allocating the transaction price to the performance obligations; and 5. Recognizing revenue when, or as, the performance obligations are satisfied. We account for a contract with a customer when there is approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Non-cancellable purchase orders received from customers to deliver a specific quantity of product, when combined with our order confirmation, in exchange for future consideration, create enforceable rights and obligations on both parties and constitute a contract with a customer. Our service agreements are specified in each respective customer agreement. We identify each performance obligation at contact inception and allocate the consideration to each distinct performance obligation based on the stand-alone selling prices of each performance obligation. We recognize revenue from the service agreements over time depicting the pattern of service delivery and recognizes the costs associated with these contracts as incurred. We recognize revenue when, or as, our performance obligations under the terms of a contract with our customer are satisfied. This happens when we transfer control of our products and risk of loss to the customer or when title passes upon shipment. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring our products. Taxes collected from customers and remitted to governmental authorities are excluded from revenues. The Company recognizes its revenue from direct product sales which is recognized at a point in time when the performance obligation is satisfied upon delivery of the product. Revenue is recorded in an amount that reflects that consideration we expect to be entitled to in exchange for those goods or services. We have elected to treat shipping and handling activities as fulfillment costs. Cost of revenue Cost of revenue consists primarily of cost associated with purchase of finished goods. Also, the Company elected to expense the cost related to the service agreements as incurred under ASC Topic 606 as the period of benefit is less than one year. Research and Development Cost Costs related to research and development are expensed as incurred. Stock-Based Compensation The Company has issued common stock awards under three equity incentive plans. Origin measures stock options and other stock-based awards granted to employees, directors and other service providers based on their fair value on the date of grant and recognizes compensation expenses of those awards over the requisite service period, which is generally the vesting period of the respective award. In addition, the Company capitalized stock-based compensation related to employees whose costs are necessary incurred to bring the asset to its intended use. For awards with performance conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. Origin applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Origin estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model and the grant date closing stock price for RSU awards and performance awards. The Black-Scholes option-pricing model requires the use of highly subjective assumptions including: • Expected term – The expected term of the options is based on the simplified method, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option which averages an award’s vesting term and its contractual term. • Expected volatility – The Company uses the trading history of various companies in its industry sector in determining an estimated volatility factor. • Expected dividend – The Company has not declared common stock dividends and does not anticipate declaring any common stock dividends in the foreseeable future. • Forfeiture – The Company estimates forfeitures based on historical activity and considers voluntary and involuntary termination behavior as well as analysis of actual historical option forfeitures, netting the estimated expense by the derived forfeiture rate. • Risk-free interest rate – The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with the same or substantially equivalent remaining term. Income Taxes Deferred income taxes are determined using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when the expected recognition of a deferred income tax asset is considered to be unlikely. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes interest and penalties related to income tax matters as a component of income tax expenses. Functional Currency Translation The functional currency of the Company’s wholly-owned Canadian subsidiaries is the Canadian dollar, whereby their assets and liabilities are translated at period-end exchange rates except for non-monetary capital transactions and balances, which are translated at historical rates. All income and expense amounts of the Company are translated at average exchange rates for the respective period. Translation gains and losses are not included in determining net income (loss) but are accumulated in a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in the determination of net income (loss) in the period in which they occur. These amounts are included in other income (expenses), net, of the unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). Comprehensive Income (Loss) The Company’s comprehensive income or loss consists of net income or loss and other comprehensive income or loss. Foreign currency translation gains or losses and unrealized gains or losses on available-for-sale marketable debt securities are included in the Company’s other comprehensive income (loss). Basic and Diluted Net Income (Loss) Per Share Basic net income (loss) per common share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For the purposes of the diluted net income (loss) per share calculation, the convertible preferred stock, common stock options, RSU awards, performance stock awards, convertible preferred stock warrants, common stock warrants, convertible notes, earnout shares, and Sponsor Vesting Shares (as defined below) are considered to be potentially dilutive securities. Basic and diluted net income (loss) per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. All series of the Company’s convertible preferred stock are considered to be participating securities because, in addition to cumulative dividends, all holders are entitled to receive a non-cumulative dividend on a pari passu basis in the event that a dividend is paid on the common stock. The two-class method requires income or loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income or loss for the period had been distributed. The holders of the convertible preferred stock do not have a contractual obligation to share in the Company’s losses. Accordingly, the Company’s net income (loss) is attributed entirely to common stockholders. Reclassifications Certain amounts on the balance sheet in prior periods have been condensed to conform with the current presentation for the six months ended June 30, 2023. Segment Reporting The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company began to recognize revenue in 2023. We recognize revenue when, or as, our performance obligations under the terms of a contract with our customer are satisfied. We generally procure, will produce, and sell product to be utilized in the manufacturing of finished products, for which we recognize revenue upon shipment. Our service contracts generally pay us at the commencement of the agreement and then at additional intervals as outlined in each contract. We recognize contract liabilities for such payments and then recognize revenue as we satisfy the related performance obligations. To the extent collectible revenue recognized under this method exceeds the consideration received, we recognize contract assets for such unbilled consideration. The Company recognized $6.9 million and $8.6 million revenue during the three and six months ended June 30, 2023 with no revenues recognized in the prior periods in 2022.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2023
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In October 2021, the FASB issued ASU 2021-08, Business Combinations (“Topic 805”), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . This update improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) recognition of an acquired contract liability; and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. Specifically, the update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers . The amendments in this update are effective for the Company in the fiscal year beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted the new standard as of January 1, 2023. The adoption of the standard had no material impact on the Company’s financial results. In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (“Topic 815”) (“ASU 2022-01”). This update clarifies the guidance in Topic 815 on fair value hedge accounting of interest rate risk for portfolios and financial assets. Among other things, the amended guidance established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible and renamed that method the “portfolio layer” method. ASU 2022-01 is effective January 1, 2023. The Company adopted the new standard as of January 1, 2023. The adoption of the standard had no material impact on the Company’s financial results. In September 2022, the FASB issued ASU 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50) . These amendments in this update improves financial reporting by requiring new disclosures about programs thereby allowing financial statement users to better consider the effect of the programs on the Company’s working capital, liquidity and cash flows over time. The amendments in this update are effective for the Company in the fiscal year beginning after December 15, 2022, including interim periods within that fiscal year. The Company adopted the new standard as of January 1, 2023. The adoption of the standard had no material impact on the Company’s financial results. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions , which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. This guidance also requires certain disclosures for equity securities subject to contractual sale restrictions. The new guidance is required to be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. This guidance is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows: Fair Value as of June 30, 2023 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash, cash equivalents and restricted cash $ 66,013 $ — $ — $ 66,013 Marketable securities — 152,170 — 152,170 Derivative asset — 160 — 160 Total fair value $ 66,013 $ 152,330 $ — $ 218,343 Liabilities: Assumed common stock warrants (Public) $ 17,869 $ — $ — $ 17,869 Assumed common stock warrants (Private Placement) — 8,380 — 8,380 Earnout liability — — 22,386 22,386 Derivative liability — 9 — 9 Total fair value $ 17,869 $ 8,389 $ 22,386 $ 48,644 Fair Value as of December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash, cash equivalents and restricted cash $ 108,348 $ — $ — $ 108,348 Marketable securities — 215,464 — 215,464 Total fair value $ 108,348 $ 215,464 $ — $ 323,812 Liabilities: Assumed common stock warrants (Public) $ 21,015 $ — $ — $ 21,015 Assumed common stock warrants (Private Placement) — 9,856 — 9,856 Earnout liability — — 42,533 42,533 Derivative liability — 344 — 344 Total fair value $ 21,015 $ 10,200 $ 42,533 $ 73,748 The Company performs routine procedures such as comparing prices obtained from independent sources to ensure that appropriate fair values are recorded. The marketable securities are categorized as Level 2 instruments as the estimated fair value was determined based on the estimated or actual bids and offers of the marketable securities in an over-the-counter market on the last business day of the period. All of the Company’s cash, cash equivalents, restricted cash, marketable securities and foreign currency derivative contracts are classified within Level 1 or Level 2 because the Company’s cash, cash equivalents, restricted cash, marketable securities and foreign currency derivative contracts are valued using quoted market prices or alternative pricing sources and models utilizing observable market inputs. Because the transfer of Private Placement Warrants to anyone outside of certain permitted transferees of Artius Acquisition Partners LLC (the “Sponsor”) would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, the Company determined that the fair value of each Private Placement Warrant is consistent with that of a Public Warrant. Accordingly, the Private Placement Warrants are classified as Level 2 financial instruments. The value of the Earnout liability (Note 13) is classified as Level 3 measurements under the fair value hierarchy, as these liabilities have been valued based on significant inputs not observable in the market. A gain of $7.5 million and $20.4 million during the three and six months ended June 30, 2023, respectively, and a gain of $33.2 million and $48.4 million during the three and six months ended June 30, 2022, respectively, was recorded on the unaudited Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) in the change in fair value of earnout liability. As of June 30, 2023 and December 31, 2022, the carrying values of cash and cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to their short-term nature. Marketable Securities The Company’s marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. Amortized cost net of unrealized gain (loss) is equal to fair value. The following table summarized the marketable securities by major security type as follows: As of June 30, 2023 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds $ 74,647 $ 54 $ (2,989) $ 71,712 Asset-backed securities 65,077 12 (3,169) 61,920 U.S. government and agency securities 18,884 — (677) 18,207 Foreign government and agency securities 375 — (44) 331 Total marketable securities $ 158,983 $ 66 $ (6,879) $ 152,170 As of December 31, 2022 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 17,568 $ 38 $ — $ 17,606 Corporate bonds 115,134 — (4,923) 110,211 Asset-backed securities 70,825 8 (3,885) 66,948 U.S. government and agency securities 19,308 — (917) 18,391 Foreign government and agency securities 375 — (37) 338 Municipal/provincial bonds and other 2,000 — (30) 1,970 Total marketable securities $ 225,210 $ 46 $ (9,792) $ 215,464 The realized gains and losses are included in other income (expenses) on the unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). We sold marketable securities for proceeds of $2,462.9 million and $1,647.8 million during the six months ended June 30, 2023 and 2022, respectively. As a result of those sales, we realized losses of $0.7 million and $0.5 million during the six months ended June 30, 2023 and 2022, respectively, and a gain of $0.1 million and zero during the three months ended June 30, 2023 and 2022, respectively. We regularly review our available-for-sale marketable securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The aggregate fair value of the marketable securities in unrealized loss position was $137.8 million and $193.5 million as of June 30, 2023 and December 31, 2022, respectively. The unrealized losses were attributable to changes in interest rates that impacted the value of the investments, and not related to increased credit risk. Accordingly, we have not recorded an allowance for credit losses associated with these investments. The contractual maturities of the investments classified as marketable securities are as follows: As of June 30, 2023 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Corporate bonds $ 55,613 $ 16,099 $ — $ 71,712 Asset-backed securities — 910 61,010 61,920 U.S. government and agency securities 7,851 7,538 2,818 18,207 Foreign government and agency securities — 331 — 331 Total marketable securities $ 63,464 $ 24,878 $ 63,828 $ 152,170 As of December 31, 2022 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Commercial paper $ 17,606 $ — $ — $ 17,606 Corporate bonds 74,797 35,414 — 110,211 Asset-backed securities 1,907 4,833 60,207 66,947 U.S. government and agency securities 7,719 7,480 3,192 18,391 Foreign government and agency securities — 338 — 338 Municipal/provincial bonds and other 1,971 — — 1,971 Total marketable securities $ 104,000 $ 48,065 $ 63,399 $ 215,464 Derivative Asset and Liabilities

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant, and equipment consisted of the following: (in thousands) June 30, 2023 December 31, 2022 Land $ 11,331 $ 11,358 Pilot plant 4,767 4,599 Lab equipment 2,820 2,526 Machinery and equipment 1,005 948 Computer and other equipment 1,180 598 Construction in process 205,061 138,847 Total 226,164 158,876 Less accumulated depreciation and amortization (5,357) (4,693) Total property, plant, and equipment, net $ 220,807 $ 154,183 The depreciation expense totaled $0.3 million and $0.6 million during the three and six months ended June 30, 2023, respectively, and $0.1 million and $0.3 million during the three and six months ended June 30, 2022, respectively. At June 30, 2023 and December 31, 2022, the Company capitalized $1.4 million and $1.1 million, respectively, of interest cost into Origin 1. At June 30, 2023 and December 31, 2022, the Company capitalized $3.2 million and $1.9 million, respectively, of stock-based compensation related to employees whose costs are necessarily incurred to bring the asset to its intended use. At June 30, 2023 and December 31, 2022 a cumulative translation adjustment of $(3.3) million and $3.0 million, respectively, is included in total property, plant, and equipment as a result of foreign currency transaction gains and losses.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets consisted of the following: (in thousands) June 30, 2023 December 31, 2022 Patents $ 413 $ 404 Less accumulated amortization (271) (244) Total intangible assets $ 142 $ 160

Consortium Agreement

Consortium Agreement	6 Months Ended
	Jun. 30, 2023
Transfers and Servicing [Abstract]
Consortium Agreement	Consortium Agreement In December 2016, the Company entered into a consortium agreement with two Legacy Origin Series B preferred stock investors to collaborate on development of a process to commercialize bio-based, decarbonizing materials for application on an industrial scale at a competitive price. Under the consortium agreement, the Company received $0.5 million. The agreement expires once performance of the research and development program has been completed. In August 2018, the agreement was amended, whereby a Legacy Origin Series C preferred stock investor (the “Legacy Origin Series C Investor”, and collectively with the two Legacy Origin Series B investors, the “Legacy Origin Investors”) was added to the agreement and committed to invest $1.5 million of research and development in the consortium. As of June 30, 2023, the Legacy Origin Series C Investor had not invested any funds in the consortium. In 2020, an additional counterparty was added to the consortium agreement. The funds received under the consortium agreement was recorded as other income, net in the unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). During the three and six months ended June 30, 2023 and 2022, the Company did not receive any funds under the consortium agreement.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory balances consist of the following: (in thousands) June 30, 2023 December 31, 2022 Finished goods $ 331 $ — Raw materials 15 — Total $ 346 $ —

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Notes Payable	Notes PayableThe Company maintains eight separate offtake supply agreements (the “Offtake Agreements”). Two of the eight Offtake Agreements are with the same customer and pertain to supply of product from Origin 1 and Origin 2, respectively. Pursuant to the Offtake Agreements, the Company will construct manufacturing plants with specific capacity and product quality requirements within certain timeframes for the manufacture of product for sale to the counterparties to the agreements, and the counterparties will make purchases at a set price, subject to adjustments, all as defined in the agreements. Legacy Origin received a $5.0 million prepayment from a customer for product from Origin 1 pursuant to one of these Offtake Agreements, which Legacy Origin entered into in November 2016. The prepayment was to be credited against the purchase of products over the term of the Offtake Agreement. The prepayment was secured by a promissory note (the “Promissory Note”) to be repaid in cash in the event that the prepayment could not be credited against the purchase of product, for example, if Origin 1 was never constructed. The Promissory Note was collateralized substantially by Origin 1 and other assets of Origin Materials Canada Pioneer Limited. In May 2019, Legacy Origin and the customer amended the Offtake Agreement and Promissory Note. The amendment added accrued interest of $0.2 million to the principal balance of the prepayment and provided for the prepayment amount to be repaid in three annual installments rather than being applied against the purchase of product from Origin 1. On August 1, 2022, the Company and the customer further amended and restated the Promissory Note with an aggregate principal amount of $5.2 million, which is the sum of the original principal with accrued interest prior to the amendment. As a result of the amendment, the repayment dates were revised and to allow the customer to offset amounts owed for the purchase of product from the Company’s Origin 1 facility against amounts due under the Promissory Note. The repayment in the amount of $2.7 million is due on September 1, 2024, $1.9 million is due on September 1, 2025, and $1.8 million is due on September 1, 2026 (inclusive of accrued but unpaid interest of 3.5% per annum). At June 30, 2023 and December 31, 2022, the total note principal outstanding was $5.2 million and accrued interest outstanding was $0.7 million and $0.6 million, respectively. In addition, the amendment reflected the customer’s exercise of its option to enter into a new Offtake Agreement to buy a specified annual amount of product from Origin 2 for an initial term of up to 10 years.

Other Liabilities, Long-term

Other Liabilities, Long-term	6 Months Ended
	Jun. 30, 2023
Other Liabilities Disclosure [Abstract]
Other Liabilities, Long-term	Other Liabilities, Long-term In September 2019, Legacy Origin entered into a $5.0 million prepayment agreement with a counterparty for the purchase of products from Origin 1. The prepayment is to be made in two equal installments: the first $2.5 million was in October 2019 and the remaining $2.5 million is due within 30 days of the customer confirming that a sample from Origin 1 meets the customer’s specifications. The Company and customer agreed to work in good faith to execute an Offtake Agreement, the agreed terms of which are set forth in the prepayment agreement, whereby 100% of the prepayment will be applied against future purchases. The prepayment agreement provides the customer a capacity reservation of up to a specified annual volume of product from Origin 1 for a term of ten years, pursuant to the terms of an Offtake Agreement. At June 30, 2023 and December 31, 2022, the total amount outstanding on this agreement was $2.5 million. Legacy Origin received a $5.0 million prepayment from a customer for product from Origin 1 pursuant to an Offtake Agreement entered into in November 2016. The prepayment is to be credited against the purchase of products from Origin 1 over the term of the Offtake Agreement. Specifically, repayment is effected by applying a credit to product purchases each month over the first five years of operation of Origin 1 up to $7.5 million, which is equal to 150% of the prepayment amount. If product purchases are not sufficient to recover the advances, the application of the credit to purchases as payment of the advances will continue until fully repaid. The prepayment is secured by a note to be repaid in cash in the event the prepayment cannot be credited against the purchase of product, for example, if Origin 1 is never constructed. The note is collateralized substantially by Origin 1 and other assets of Origin Material Canada Pioneer Limited. If repaid in cash, the note bears an annual interest rate of the three-month London Interbank Offered Rate (“LIBOR”) plus 0.25% (5.31% at June 30, 2023) and matures five years from the commercial operation date of Origin 1, which is defined by the plant's actual production of a certain volume of product as well as its capacity to produce a certain annual volume of product. At June 30, 2023 and December 31, 2022 the total principal outstanding was $5.1 million and accrued interest outstanding was $0.4 million and $0.3 million, respectively.

Earnout Liability

Earnout Liability	6 Months Ended
	Jun. 30, 2023
Earnout Liability Disclosure [Abstract]
Earnout Liability	Earnout Liability As additional consideration for the Merger, within 10 business days after the occurrence of a “Triggering Event,” as defined below, the Company shall issue or cause to be issued to each Legacy Origin stockholder a certain number of shares of the Company Class A Common Stock. The number of such shares is equal to the product of (i) the number of shares of Company Common Stock, Company Series A Preferred Stock, Company Series B Preferred Stock, Company Series C Preferred Stock, and the net number of shares of Company Capital Stock that would be issuable in respect of "Vested Company Options" in the event such options were exercised (on a net exercise basis with respect to only the applicable exercise price, immediately prior to the “Closing” and settled in the applicable number of shares of Company Common Stock, rounded down to the nearest whole share) held by such Legacy Origin stockholder as of immediately prior to the “Effective Time”; and (ii) the “Earnout Exchange Ratio" (such issued shares of Artius Class A Common Stock, collectively, the “Earnout Shares”), where “Vested Company Options,” “Closing,” “Effective Time,” and “Earnout Exchange Ratio” have the meanings set forth in the Merger Agreement. The Company cannot be required to issue more than 25,000,000 Earnout Shares in the aggregate. A Triggering Event is defined as the following: (a) the volume weighted average price of Common Stock (“VWAP”) equaling on exceeding $15.00 for ten (b) the VWAP equaling or exceeding $20.00 for ten (c) the VWAP equaling or exceeding $25.00 for ten A Sponsor Letter Agreement was delivered in connection with the Merger such that 4.5 million of the shares held by Sponsor (“Sponsor Vesting Shares”) shall be subject forfeiture based on the same vesting requirements as the Earnout Shares. These shares shall not be transferred prior to the date in which they vest. Dividends and other distributions with respect to Sponsor Vesting Shares shall be set aside by the Company and shall be paid to the Sponsor upon the vesting of such Sponsor Vesting Shares. The Company evaluated the Earnout Liability under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”) , and concluded they do not meet the criteria to be classified in stockholders’ equity. Specifically, there are contingent exercise provisions and settlement provisions that exist. Holders may receive differing amounts of shares depending on the company’s stock price or the price paid in a change of control. All remaining shares would be issuable (or the forfeiture provisions would lapse) upon any change of control involving the Company and all remaining shares would be issuable (or the forfeiture provisions would lapse) upon a bankruptcy or insolvency of the company. This means that settlement is not solely impacted by the share price of the Company (that is, the share price observed in or implied by a qualifying change-in-control event), but also by the occurrence of a qualifying change-in-control event. This causes the arrangement to not be indexed to the Company’s own shares and liability classification is appropriate. The Company recorded these instruments as liabilities on the condensed consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in earnings at each reporting date. The earnout liability was fair valued using a Monte Carlo open-ended model. The inputs used for the model were a dividend yield of 0%, volatility of 68%, and interest rate of 4.40%. The balance of the earnout liability was $22.4 million and $42.5 million at June 30, 2023 and December 31, 2022, respectively. A gain of $7.5 million and $20.4 million during the three and six months ended June 30, 2023, respectively, and a gain of $33.2 million and $48.4 million during the three and six months ended June 30, 2022, respectively, was recorded on the unaudited Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) in the change in fair value of earnout liability.

Canadian Government Research an

Canadian Government Research and Development Program Liability	6 Months Ended
	Jun. 30, 2023
Research and Development [Abstract]
Canadian Government Research and Development Program Liability	Canadian Government Research and Development Program Liability In April 2019, the Company entered into a contribution agreement related to the research and development and construction associated with the operation of Origin 1 in which the Company will participate in a Canadian government research and development program (the “R&D Agreement”). Pursuant to the R&D Agreement, the Company will receive funding for eligible expenditures through March 31, 2023 up to the lesser of approximately 18.48% of eligible costs and $23.0 million (in Canadian dollars).The funding will be repaid over 15 years after completion of Origin 1, commencing no sooner than the third fiscal year of consecutive revenues from a commercial plant, but no later than March 2028. The maximum amount to be repaid by the Company under the R&D Agreement is 1.25 times the actual funding received, subject to the following repayment ceiling formula. Repayment of the funding will be reduced by 50% if the Company begins construction before December 31, 2024 of one or more commercial plants that operate in Canada, with costs exceeding $500.0 million (in Canadian dollars), and the plants being constructed and operational within 30 months of the final investment decision, as defined in the R&D Agreement. Once begun, repayments will be paid annually by April of each year through March 31, 2037. Payments will be determined by a formula of the funded amount based on the fiscal year gross business revenue, as defined in the R&D Agreement. The Company recorded a liability for the amount received of $7.3 million and $7.2 million at June 30, 2023 and December 31, 2022, respectively, on the Condensed Consolidated Balance Sheets in Canadian government research and development program liability.

Assumed Common Stock Warrants

Assumed Common Stock Warrants	6 Months Ended
	Jun. 30, 2023
Assumed Common Stock Warrants [Abstract]
Assumed Common Stock Warrants	Assumed Common Stock Warrants As of June 30, 2023 and December 31, 2022 there are 35,476,627 warrants outstanding. As part of Artius’s initial public offering, 24,149,960 Public Warrants were sold. The Public Warrants entitle the holder thereof to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustments. The Public Warrants may be exercised only for a whole number of shares of Common Stock. No fractional shares will be issued upon exercise of the warrants. The Public Warrants will expire on June 25, 2026 at 5:00p.m., New York City time, or earlier upon redemption or liquidation. The Public Warrants are listed on the Nasdaq under the symbol “ORGNW.” The Company may redeem the Public Warrants when exercisable, in whole and not in part, at a price of $0.01 per warrant, so long as the Company provides not less than 30 days’ prior written notice of redemption to each warrant holder, and if, and only if, the reported last sale price of the Common Stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date the Company sends the notice of redemption to the warrant holders. Simultaneously with Artius’s initial public offering, Artius consummated a private placement of 11,326,667 Private Placement Warrants with the Sponsor. The Private Placement Warrant is exercisable for one share of Class A Common Stock at a price of $11.50 per share, subject to adjustment. The Private Placement Warrants are identical to the Public Warrants, except that: (1) the Private Placement Warrants and the shares of Class A Common Stock issuable upon exercise of the Private Placement Warrants are not transferable, assignable or salable until the earliest to occur of: (i) 365 days after the date of the Closing; (ii) the first day after the date on which the closing price of the Public Shares (or any successor securities thereto) equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the date of the Closing; or (iii) the date on which Artius completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of Artius’s Public Shareholders having the right to exchange their Public Shares (or any successor securities thereto) for cash, securities or other property, subject to certain limited exceptions, (2) the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable, except if the reference value equals or exceeds $10.00 and is less than $18.00 (as described above), so long as they are held by the initial purchasers or their permitted transferees, and (3) the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will be entitled to registration rights. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable under all redemption scenarios by the Company and exercisable by such holders on the same basis as the Public Warrants. The Company concluded the Public Warrants and Private Placement Warrants, or Assumed Common Stock Warrants, meet the definition of a derivative under ASC 815 and are recorded as liabilities. Upon consummation of the Business Combination, the fair value of the Assumed Common Stock Warrants was recorded on the Condensed Consolidated Balance Sheets. The fair value of the Assumed Common Stock Warrants was remeasured on the June 30, 2023 and December 31, 2022 Condensed Consolidated Balance Sheets at $26.2 million and $30.9 million, respectively. A loss of $2.1 million and a gain of $4.6 million during the three and six months ended June 30, 2023, respectively, and a gain of $18.8 million and $17.0 million during the three and six months ended June 30, 2022, respectively, was recorded on the unaudited Condensed Consolidated Statement of Operations and Comprehensive Income (Loss).

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ EquityAs of June 30, 2023 and December 31, 2022, 1,010,000,000 shares, $0.0001 par value per share are authorized, of which, 1,000,000,000 shares are designated as Common Stock and 10,000,000 shares are designated as Preferred Stock. Common Stock Holders of the Common Stock are entitled to dividends when, as, and if, declared by the Board, subject to the rights of the holders of all classes of stock outstanding having priority rights to dividends. As of June 30, 2023, the Company had not declared any dividends. The holder of each share of Common Stock is entitled to one vote. There were 143,498,724 and 143,034,225 shares of Common Stock (including 4,500,000 Sponsor Vesting Shares not indexed to equity) outstanding as of June 30, 2023 and December 31, 2022, respectively. Employee Stock Purchase Plan The Company maintains an Employee Stock Purchase Plan (“ESPP”). The ESPP permits participants to purchase shares of our Common Stock with the purchase price of the shares at a price determined by our board, which shall not be less than 85% of the lower of the fair market value of our Common Stock on the first day of an offering or on the date of purchase. Initially, following adoption of the ESPP, the maximum number of shares of our Common Stock that may be issued under the ESPP was 1,846,710. The ESPP contains an “evergreen” share reserve feature that automatically increases the number of shares of Common Stock reserved for issuance under the plan on January 1 of each year for a period of ten years commencing on January 1, 2022 and ending on (and including) January 1, 2031 in an amount equal to the lesser of (1) one percent (1%) of the fully-diluted shares of our Common Stock on December 31st of the preceding calendar year, (2) 3,693,420 of Common Stock, or (3) such lesser number of shares as determined by our board. As of December 31, 2022, the number of shares available for issuance under the ESPP was 3,722,490. On January 1, 2023 , the number of shares of Common Stock reserved for issuance under the ESPP was automatically increased by 1,917,454 . As a result, as of June 30, 2023, the number of shares available for issuance under the ESPP was 5,639,944 . Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the ESPP. To date no stock has been offered or issued to employees under the ESPP. Equity Incentive Plans The Company maintains the following equity incentive plans: the 2010 Stock Incentive Plan, the 2020 Equity Incentive Plan, and the 2021 Equity Incentive Plan, each as amended (together, the “Stock Plans”). Upon closing of the Business Combination, awards under the 2010 Stock Incentive Plan and 2020 Equity Incentive Plan were converted at the Exchange Ratio and the 2021 Equity Incentive Plan was adopted and approved. Origin may grant a wide variety of equity securities under the Stock Plans, including incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance-based stock awards, and other awards. The Company has granted incentive stock options, RSU awards, and performance awards under the Stock Plans. Under the Stock Plans, options must be issued at exercise prices no less than the estimated fair value of the stock on the date of grant and are exercisable for a period not exceeding 10 years from the date of grant. Options granted to employees under the Stock Plan generally vest 25% one year from the vesting commencement date and 1/36th per month thereafter, although certain arrangements call for vesting over other periods. Options granted to non-employees under the Stock Plan vest over periods determined by the Board (generally immediate to four years). RSU awards granted to employees under the 2021 Equity Incentive Plan require a service period of three years and generally vest 33.3% annually over the three-year service period. Under the Stock Plans, the fair value of RSU awards and performance-based stock awards are determined to be the grant date closing stock price. For awards with performance-based conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. The performance-based stock awards are subject to vesting based on a performance-based condition and a service-based condition. The performance-based stock awards will vest in a percentage of the target number of shares between 0% and 300%, depending on the extent the performance conditions are achieved. Initially, following adoption of the 2021 Equity Incentive Plan, there were 18,467,109 shares of Common Stock reserved for issuance under the Stock Plans. The 2021 Equity Incentive Plan contains an “evergreen” share reserve feature that automatically increases the number of shares of Common Stock reserved for issuance under the plan on January 1 of each year for a period of ten years commencing on January 1, 2022 and ending on (and including) January 1, 2031 in an amount equal to five percent (5%) of the fully-diluted Common Stock on December 31 of the preceding year unless our board acts prior to January 1 to increase the share reserve by a lesser amount. The number of shares added to the share reserve on January 1 of a given year is reduced automatically to the extent necessary to avoid causing the share reserve to exceed fifteen percent (15%) of the fully-diluted Common Stock on December 31 of the preceding year. As of December 31, 2022, there were 27,846,011 shares of common stock reserved under the Stock Plans. On January 1, 2023, the number of shares of Common Stock reserved for issuance under the 2021 Equity Incentive Plan was automatically increased by 915,805 shares pursuant to the 2021 Plan’s “evergreen” provision. As a result, a s of June 30, 2023, there were 28,761,816 shares of Common Stock reserved available under the Stock Plans. The following tables summarize stock option activity under the Stock Plans: Outstanding Options Weighted Weighted Average Balance as of December 31, 2022 6,471,062 $ 0.17 7.29 Granted — — Exercised (163,096) 0.14 Forfeited / canceled — — Balance as of March 31, 2023 6,307,966 $ 0.17 7.03 Granted — — Exercised (208,807) 0.15 Forfeited / canceled (794) 0.14 Balance as of June 30, 2023 6,098,365 $ 0.17 6.77 Vested and expected to vest at June 30, 2023 6,098,365 During the three and six months ended June 30, 2023, the Company did not grant any stock options. As of June 30, 2023 and December 31, 2022, there were 15,694,899 and 15,728,837 awards, respectively, available for grant under the Stock Plans. As of June 30, 2023 and December 31, 2022 there were 3,651,658 and 3,588,523 exercisable options, respectively. The total intrinsic value of the options exercised was $0.9 million and $1.8 million during the three and six months ended June 30, 2023, respectively, and $5.0 million and $5.7 million during the three and six months ended June 30, 2022, respectively. The intrinsic value of options exercised during each fiscal year is calculated as the difference between the market value of the stock at the time of exercise and the exercise price of the stock option. The aggregate intrinsic value of options vested and expected to vest at June 30, 2023 and December 31, 2022 were $24.9 million and $28.7 million. As of June 30, 2023 and December 31, 2022, the Company had stock-based compensation of $3.2 million and $4.7 million, respectively, related to unvested stock options not yet recognized that are expected to be recognized over an estimated weighted average period of 1.2 years and 1.7 years, respectively. The Company issued 2,920,732 of performance and market-based stock options during 2020. During the quarter ended March 31, 2021, the Company modified the vesting schedule of 529,119 of these performance and market based stock options such that vesting at 1/48th per month would commence upon signing of the Business Combination. The Company entered into the Merger Agreement on February 16, 2021 resulting in the commencement of expense recognition related to these 529,119 options during the quarter ended March 31, 2021. For the remaining 2,391,613 performance and market-based stock options, expense commenced on the close date of the Merger, June 25, 2021, as that is the date when the performance condition was achieved. The following table summarizes the RSU award and performance-based stock award activity: Outstanding Weighted-average grant date fair value Unvested balance at December 31, 2022 6,371,950 $ 6.24 Granted - RSU awards 163,544 5.15 RSU awards vested and converted to shares (70,670) 5.39 Forfeited - RSU awards (50,212) 5.53 Forfeited - performance-based stock awards (35,625) 5.46 Unvested balance March 31, 2023 6,378,987 $ 6.22 Granted - RSU awards 387,841 4.14 RSU awards vested and converted to shares (50,693) 7.01 Forfeited - RSU awards (118,008) 6.01 Forfeited - performance-based stock awards (21,150) 5.56 Unvested balance June 30, 2023 6,576,977 $ 6.10 Expected to vest 4,414,827 The RSU awards, which upon vesting entitle the holder to be issued on a future date the number of shares of Common Stock that is equal to the number of restricted stock units subject to the RSU awards. The total fair value of shares vested was $0.2 million and $0.6 million during the three and six months ended June 30, 2023, respectively, and $0.7 million and $0.7 million during the three and six months ended June 30, 2022, respectively. As of June 30, 2023, the performance conditions for the granted performance-based stock awards were not probable of being met, therefore no performance award stock compensation has been recorded. There were no performance-based stock awards vested during the three and six months ended June 30, 2023 and 2022. As of June 30, 2023, there were 1,976,725 unvested performance-based awards subject to certain performance criteria for vesting. The vesting period for RSU awards is generally three years. Total remaining compensation expense for RSU awards to be recognized under the 2021 Equity Incentive Plan is $19.4 million as of June 30, 2023, and will be amortized on a straight-line basis over the remaining vesting periods. Total remaining compensation expense for performance-based stock awards to be recognized will be recognized over the requisite service periods once the performance-based conditions are deemed to be probable.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe provision for income taxes is recorded at the end of each interim period based on the Company’s best estimate of its effective income tax rate expected to be applicable for the full fiscal year, adjusted for any discrete items during the quarter. The Company has recorded an income tax provision during the three months ended June 30, 2023 of $0.1 million related to foreign withholding taxes on some of its revenue. Other than withholding taxes, there is no provision for income taxes because the Company has incurred operating losses since inception. The Company’s effective income tax rate was (1.68)% and 3.29% for the three and six months ended June 30, 2023, respectively, and zero for three and six months ended June 30, 2022. The Company continues to maintain a full valuation allowance on its net deferred tax assets.

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	LeasesThe Company leases office space and research and development space in Sacramento, California and Sarnia, Ontario under non-cancelable lease agreements and leases various office equipment, warehouse space, and temporary fencing. The operating leases have remaining lease terms of one

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments In May 2018, the Company executed the agreements for certain services, to facilitate the development and thus bring Origin 1 to the condition necessary for its intended use, commencing in different periods between July 2018 and September 2019, and all generally for five-year periods. The agreements are generally automatically extended for one-year periods thereafter. The agreements include annual fixed payments subject to escalation clauses at the beginning of each calendar year, as defined in the agreement. The minimum fixed payments are $0.4 million per year over the fixed term. Certain of the agreements include quantities that are based on volumes, as defined in the applicable agreements. The Company is also responsible for applicable taxes under these agreements. The total amount capitalized into Property, Plant and Equipment, Net under the agreement was $0.0 million and $0.2 million during the three and six months ended June 30, 2023, respectively, and $0.4 million and $0.5 million during the three and six months ended June 30, 2022, respectively. In April 2023, the Company entered into an agreement for conversion of materials produced by Origin 1 into certain derivatives. Pursuant to the agreement, the Company agreed to purchase conversion services for a certain minimum quantity of product on a take-or-pay basis for a term of 5 years beginning in 2025 for an aggregate total cost of $35 million. The Company made an advance payment to the counterparty, which is included in the foregoing aggregate total, and the agreement provides for the Company to be fully reimbursed for the advance payment in the form of a discount on conversion services over the term. The agreement gives the Company the right, but not the obligation, to purchase conversion services for an additional quantity of product in 2024 and stipulates a reduction in the take-or-pay commitment under certain circumstances including the counterparty's inability to meet the required product specification. The agreement automatically renews for an additional year unless either party gives advance notice of an intention not to renew. In addition, either party may terminate the agreement in the event of the other party's insolvency or breach of a material term. In February 2023, the Company entered into a nonexclusive patent license agreement for use in connection with production at a specific licensed facility. The license expires upon cessation of production at that facility. The Company made a nonrefundable €5 million deposit in 2022 toward securing the license and, as a result of signing the license agreement, made an additional payment of €7.5 million during first quarter 2023 and may make additional payments depending on the achievement of certain milestones. The total payment is included in other long-term assets. In connection with this license, the Company entered into a conditional offtake agreement under which the licensor will supply the Company with a certain amount of the same type of products to be produced at the licensed facility in order to accelerate market development for these products and related applications. In July 2017, the Company entered into a nonexclusive patent license agreement for $0.1 million, which expires upon expiration of the last to expire of the licensed patents. Under this agreement, the Company will pay less than $0.1 million minimum royalty payments per year and, if the Company develops and sells certain products based on the licensed patents. Certain products that Origin is currently developing and anticipates selling are expected to utilize these patents. In December 2016, the Company entered into a patent license agreement for $0.5 million, which expires upon expiration of the last to expire of the licensed patents. Under this agreement, if the Company develops and sells specific products based on the patents, the Company would pay a royalty up to a cumulative $0.5 million from Origin 1, whereby no further payments will be due for any production at Origin 1. If production of those products occurs at subsequent facilities, the Company will pay an upfront license fee royalty and a variable royalty based on production at that subsequent facility, capped at an aggregate $10.0 million per facility. Certain products that the Company is currently developing and anticipates selling are expected to utilize these patents. No payments were made during the three and six months ended June 30, 2023 or 2022. In November 2016, the Company entered into a nonexclusive patent license agreement, which expires upon expiration of the patent. Under this agreement, if the Company produces products based on the patent, the Company will pay an annual royalty upon commencement of operations on Origin 1 which will not exceed $1.0 million cumulatively. The pipeline of Company products and sales are not currently expected to be subject to this patent. The annual royalty payments is less than $0.1 million. In September 2011, the Company entered into a nonexclusive patent license agreement, which expires upon expiration of the patent. Under this agreement, if the Company develops and sells specific products based on the patent, the Company would pay a royalty up to $2.0 million per year and $10.0 million in the aggregate. Certain products that the Company is currently developing and anticipates selling are expected to utilize these patents. No payments were made during the three and six months ended June 30, 2023 or 2022. In June 2011, the Company entered into a nonexclusive patent license agreement, which expires upon expiration of the licensed patent. Under this agreement, the Company pays less than $0.1 million royalty fee annually and if the Company develops and sells specific products based on the patent, 0.4% of net sales. The pipeline of Company products and sales are not currently expected to be subject to this patent. We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes and certain studies. Commitments under service agreements are subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work. Contingencies At times there may be claims and legal proceedings generally incidental to the normal course of business that are pending or threatened against the Company. Although the Company cannot predict the outcome of these matters when they arise, in the opinion of management, any liability arising from them will not have a material adverse effect on the consolidated financial position, results of operations, or liquidity of the Company. At June 30, 2023 and December 31, 2022, there were no material claims or legal proceedings pending or threatened against the Company.

Basic and Diluted Net Income Pe

Basic and Diluted Net Income Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	Basic and Diluted Net Income Per Share The following table sets forth the computation of basic and diluted net income (loss) per share attributable to common stockholders, which excludes Sponsor Vesting Shares which are legally outstanding, but subject to return to the Company. Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average common shares outstanding during the period, plus the dilutive effect of the stock options and RSU awards, as applicable pursuant to the treasury stock method. The following table sets forth the computation of basic and diluted net income (loss) per share: (In thousands, except for share and per share amounts) Three Months Ended Six Months Ended 2023 2022 2023 2022 Numerator: Net income (loss) attributable to common stockholders—Basic $ (6,464) $ 46,931 $ 3,305 $ 54,277 Net income (loss) attributable to common stockholders—Diluted $ (6,464) $ 46,931 $ 3,305 $ 54,277 Denominator: Weighted-average common shares outstanding—Basic (1) 139,265,248 137,141,655 139,154,557 136,985,440 Stock options — 4,889,299 3,730,144 5,010,955 RSU awards — 164,683 154,734 82,357 Weighted-average common shares outstanding—Diluted (1) 139,265,248 142,195,637 143,039,435 142,078,752 Net income (loss) per share—Basic $ (0.05) $ 0.34 $ 0.02 $ 0.40 Net income (loss) per share—Diluted $ (0.05) $ 0.33 $ 0.02 $ 0.38 (1) Excludes weighted-average Sponsor Vesting Shares subject to return of 4,500,000 shares as of June 30, 2023 and 2022. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The following potentially dilutive securities for common stock were outstanding and excluded from diluted earnings per share as they are subject to performance or market conditions that were not achieved as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Options to purchase common stock 1,481,531 1,481,531 1,481,531 1,481,531 Performance-based stock awards 2,162,150 2,610,500 2,162,150 2,610,500 Earnout shares 25,000,000 25,000,000 25,000,000 25,000,000 Sponsor vesting shares 4,500,000 4,500,000 4,500,000 4,500,000 The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net income (loss) per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended Six Months Ended 2023 2022 2023 2022 Options to purchase common stock 4,616,840 — — — Warrants to purchase common stock 35,476,627 35,476,627 35,476,627 35,476,627 RSU awards 4,416,828 — — —

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net income (loss)	$ (6,464)	$ 46,931	$ 3,305	$ 54,277

Insider Trading Arrangements

Insider Trading Arrangements - Joshua Lee [Member]	3 Months Ended
	Jun. 30, 2023 shares
Trading Arrangements, by Individual
Name	Joshua Lee
Title	General Counsel
Adoption Date	June 15, 2023
Aggregate Available	30,253

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”).
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of revenues, costs and expenses during the reporting periods. Estimates made by the Company include, but are not limited to, valuation of the earnout liability, valuation of assumed common stock warrants liability, carrying amount and useful lives of property and equipment and intangible assets, impairment assessments, marketable securities, stock-based compensation expenses, probabilities of achievement of performance conditions on performance stock awards, among others. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
Unaudited Interim Condensed Consolidated Financial Statements	Unaudited Interim Condensed Consolidated Financial Statements The accompanying interim Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022, the interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), and the interim Condensed Consolidated Statements of Stockholders’ Equity and Accumulated Other Comprehensive Loss for the three and six months ended June 30, 2023 and 2022, and the interim Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022, and the notes to such interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. As permitted under those rules, we condensed or omitted certain footnotes or other financial information that are normally required by GAAP for annual financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in management’s opinion, include all adjustments consisting of only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2023 and its results of operations for the three and six months ended June 30, 2023 and 2022 and cash flows for the six months ended June 30, 2023 and 2022. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the full fiscal year or any other period.
Principles of Consolidation	Principles of Consolidation The unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents, and marketable securities. The Company maintains its cash, cash equivalents, and marketable securities accounts with financial institutions where, at times, deposits exceed federal insurance limits. Management believes that the Company is not currently exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality. While the Company has not experienced losses of these deposits to date, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business could be adversely affected.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an initial maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains such funds in cash deposits and money market accounts.
Marketable Securities	Marketable Securities The Company’s investment policy requires the Company to purchase investments that are consistent with the classification of available-for-sale securities. The Company does not buy and hold securities principally for the purpose of selling them in the near future. The Company’s policy is focused on the preservation of capital, liquidity, and return. The Company considers all of its marketable debt securities as available for use in current operations, including those with maturity dates beyond one year, and therefore classifies these securities within current assets on the condensed consolidated balance sheets. Securities are classified as available for sale and are carried at fair value, with the change in unrealized gains and losses, net of tax, reported as a separate component on the condensed consolidated statements of operations and comprehensive income (loss) until realized. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such as quoted prices, interest rates and yield curves. Securities with an amortized cost basis in excess of estimated fair value are assessed to determine what amount of the excess, if any, is caused by expected credit losses. Expected credit losses on securities are recognized in other income (expenses), net on the condensed consolidated statements of operations and comprehensive income (loss), and any remaining unrealized gains and losses, net of taxes, are included in accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ equity and accumulated other comprehensive loss. For the purposes of computing realized and unrealized gains and losses, the cost of securities sold is based on the specific-identification method. Amortization of discounts and premiums, net, and interest on securities classified as available for sale are included as a component of interest income within other income (expenses). The nature of these financial instruments include instruments for which quoted prices are available but traded less frequently, instruments whose fair value has been derived using a model where inputs to the model are directly observable in the market, or can be derived principally from or corroborated by observable market data, and instruments that are fair valued using other financial instruments, the parameters of which can be directly observed. Level 2 financial instruments include agency mortgage-backed securities, corporate fixed income securities infrequently traded, and other securities, which primarily consist of sovereign debt, U.S. government agency securities, loans, and state and municipal securities.
Derivative Financial Instruments	Derivative Financial Instruments The Company enters into foreign currency derivative contracts with financial institutions to reduce foreign exchange risk related to marketable securities. The Company uses forward currency derivative contracts to minimize the Company’s exposure to balances primarily denominated in the British Pound Sterling and Australian Dollar. The Company’s foreign currency derivative contracts, which are not designated as hedging instruments, are used to reduce the exchange rate risk associated primarily with marketable securities. The Company’s derivative financial instruments program is not designated for trading or speculative purposes. Outstanding foreign currency derivative contracts are recorded at fair value on the condensed consolidated balance sheets.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company applies the fair value measurement accounting standard whenever other accounting pronouncements require or permit fair value measurements. Fair value is defined in the accounting standard as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy under current accounting guidance prioritizes the inputs to valuation techniques used to measure fair value into three broad levels (Level 1, Level 2, and Level 3). Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk) in a principal market. The carrying amounts of working capital balances approximate their fair values due to the short maturity of these items. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest rate, currency, or credit risks arising from its financial instruments. We have determined the fair value of debt approximates the carrying value due to the standard terms of the arrangement including but not limited to the amount borrowed, the term, and the interest rate.
Accounts Receivable	Accounts Receivable We record accounts receivable at the stated amount of the transactions with our customers, and we do not charge interest. The allowance for credit losses, known as the Current Expected Credit Losses ("CECL") model, is our best estimate of the amount of probable credit losses associated with our accounts receivable. We determine the allowance based on current conditions, and reasonable and supportable forecasts. Past-due balances are reviewed individually for collectability. We charge off account balances against the allowance after we have exhausted all means of collection and we consider the potential for recovery to be remote. Our accounts receivable generally have net 30 to net 90-day payment terms, and we usually receive consideration in accordance with the payment terms of the contract. As of June 30, 2023 , we do not have any allowance for credit losses.
Other Receivables	Other Receivables Other receivables consist of amounts due from foreign governmental entities related to the Canadian harmonized sales tax (“HST”) and goods and services tax (“GST”) for goods and services transacted in Canada, and amounts due from cash collateral held by others for foreign currency derivative contracts.
AgriScience Grant	AgriScience Grant In January 2019, the Company entered into an agreement in which it will participate in the AgriScience Program Cluster Component grant through the Canadian Agricultural Partnership, whereby the Company will receive reimbursements for eligible expenditures up to approximately $1.8 million (in Canadian dollars) incurred through March 2023. Grants are received through reimbursements from the Canadian government and recognized, upon completion of scope of services on a quarterly basis. Grants are recognized as a reduction of property, plant, and equipment or expenses based on the nature of the cost the grant is reimbursing.
Inventory	Inventory Inventories are stated at the lower of cost or net realizable value. Cost is determined using a weighted-average cost approach, assuming full absorption of direct and indirect manufacturing costs, or based on cost of purchasing from our vendors. If inventory costs exceed expected net realizable value due to obsolescence or lack of demand, valuation adjustments are recorded for the difference between the cost and the expected net realizable value.
Property, Plant, and Equipment	Property, Plant, and Equipment Property, plant, and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. Depreciation normally begin when assets are ready for its intended use. Leasehold improvements are amortized using the straight-line method over the shorter of their estimated useful lives or the lease term. Major additions and improvements are capitalized, while replacements, repairs, and maintenance that do not extend the life of an asset are charged to operations. We depreciate plants over a maximum life of 40 years and plant improvements over the shorter of the asset life or remaining useful life of the plants structure using the straight-line method. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts. Costs incurred to acquire, construct or install property, plant, and equipment during the construction stage of a capital project and costs capitalized in conjunction with major improvements that have not yet been placed in service are recorded as construction in progress, and accordingly are not currently being depreciated.
Intangible Assets	Intangible Assets Intangible assets are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the respective assets, ranging from 7 to 15 years. The cost of servicing the Company’s patents is expensed as incurred. Upon retirement or sale, the cost of intangible assets is disposed of and the related accumulated amortization is removed from the accounts. The Company reviews its long-lived assets, including property, equipment, software and intangibles, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. If indicators of impairment exist, management identifies the asset group which includes the potentially impaired long-lived asset, at the lowest level at which there are separate, identifiable cash flows. If the total of the expected undiscounted future net cash flows for the asset group is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset.
Assumed Common Stock Warrants Liability	Assumed Common Stock Warrants Liability The Company assumed 24,149,960 public warrants (the “Public Warrants”) and 11,326,667 private placement warrants (the “Private Placement Warrants”, and the Public Warrants together with the Private Placement Warrants, the “Assumed Common Stock Warrants” or “Warrants”) upon the Business Combination, all of which were issued in connection with Artius’ initial public offering and entitle each holder to purchase one share of Class A common stock at an exercise price of at $11.50 per share. As of June 30, 2023, 24,149,960 Public Warrants and 11,326,667 Private Placement Warrants are outstanding. The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the warrants may be cashless exercised. The Private Placement Warrants are transferable, assignable or salable in certain limited exceptions. The Private Placement Warrants are exercisable for cash or on a cashless basis, at the holder’s option, and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will cease to be Private Placement Warrants, and become Public Warrants and be redeemable by the Company and exercisable by such holders on the same basis as the other Public Warrants. The Company evaluated the Assumed Common Stock Warrants under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”)
Earnout Liability	Earnout Liability The Company has recorded an earnout liability related to future contingent equity shares related to the Business Combination (Note 13). The Company recorded these instruments as liabilities on the Condensed Consolidated Balance Sheets at fair value, with subsequent changes in their respective fair values recognized in earnings at each reporting date.
Leases	Leases The Company has leases for office space and equipment, some of which have escalating rentals during the initial lease term and during subsequent optional renewal periods. The Company accounts for its leases under ASC 842, Leases . The Company recognizes a right-of-use asset and lease liability for leases based on the net present value of future minimum lease payments. Lease expense is recognized on a straight-line basis over the non-cancelable lease term and renewal periods that are considered reasonably certain to be exercised.
Revenue Recognition	Revenue Recognition The Company began to recognize revenue in 2023. Our revenues are from product sales and service agreements. The majority of our contracts with customers typically contain multiple products and services. We account for individual products and services separately if they are distinct-that is, if a product or service is separately identifiable from other items in the contract and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”) . The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or service to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our product revenue and collaborative research and development agreements, we perform the following steps: 1. Identifying the contract with a customer; 2. Identifying the performance obligations in the contract; 3. Determining the transaction price; 4. Allocating the transaction price to the performance obligations; and 5. Recognizing revenue when, or as, the performance obligations are satisfied. We account for a contract with a customer when there is approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Non-cancellable purchase orders received from customers to deliver a specific quantity of product, when combined with our order confirmation, in exchange for future consideration, create enforceable rights and obligations on both parties and constitute a contract with a customer. Our service agreements are specified in each respective customer agreement. We identify each performance obligation at contact inception and allocate the consideration to each distinct performance obligation based on the stand-alone selling prices of each performance obligation. We recognize revenue from the service agreements over time depicting the pattern of service delivery and recognizes the costs associated with these contracts as incurred. We recognize revenue when, or as, our performance obligations under the terms of a contract with our customer are satisfied. This happens when we transfer control of our products and risk of loss to the customer or when title passes upon shipment. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring our products. Taxes collected from customers and remitted to governmental authorities are excluded from revenues. The Company recognizes its revenue from direct product sales which is recognized at a point in time when the performance obligation is satisfied upon delivery of the product. Revenue is recorded in an amount that reflects that consideration we expect to be entitled to in exchange for those goods or services. We have elected to treat shipping and handling activities as fulfillment costs. Cost of revenue Cost of revenue consists primarily of cost associated with purchase of finished goods. Also, the Company elected to expense the cost related to the service agreements as incurred under ASC Topic 606 as the period of benefit is less than one year.
Research and Development Cost	Research and Development Cost Costs related to research and development are expensed as incurred.
Stock-Based Compensation	Stock-Based Compensation The Company has issued common stock awards under three equity incentive plans. Origin measures stock options and other stock-based awards granted to employees, directors and other service providers based on their fair value on the date of grant and recognizes compensation expenses of those awards over the requisite service period, which is generally the vesting period of the respective award. In addition, the Company capitalized stock-based compensation related to employees whose costs are necessary incurred to bring the asset to its intended use. For awards with performance conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. Origin applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Origin estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model and the grant date closing stock price for RSU awards and performance awards. The Black-Scholes option-pricing model requires the use of highly subjective assumptions including: • Expected term – The expected term of the options is based on the simplified method, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option which averages an award’s vesting term and its contractual term. • Expected volatility – The Company uses the trading history of various companies in its industry sector in determining an estimated volatility factor. • Expected dividend – The Company has not declared common stock dividends and does not anticipate declaring any common stock dividends in the foreseeable future. • Forfeiture – The Company estimates forfeitures based on historical activity and considers voluntary and involuntary termination behavior as well as analysis of actual historical option forfeitures, netting the estimated expense by the derived forfeiture rate. • Risk-free interest rate
Income Taxes	Income Taxes Deferred income taxes are determined using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when the expected recognition of a deferred income tax asset is considered to be unlikely.
Functional Currency Translation	Functional Currency Translation The functional currency of the Company’s wholly-owned Canadian subsidiaries is the Canadian dollar, whereby their assets and liabilities are translated at period-end exchange rates except for non-monetary capital transactions and balances, which are translated at historical rates. All income and expense amounts of the Company are translated at average exchange rates for the respective period. Translation gains and losses are not included in determining net income (loss) but are accumulated in a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in the determination of net income (loss) in the period in which they occur. These amounts are included in other income (expenses), net, of the unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).
Comprehensive Income (Loss)	Comprehensive Income (Loss) The Company’s comprehensive income or loss consists of net income or loss and other comprehensive income or loss. Foreign currency translation gains or losses and unrealized gains or losses on available-for-sale marketable debt securities are included in the Company’s other comprehensive income (loss).
Basic and Diluted Net Income (Loss) Per Share	Basic and Diluted Net Income (Loss) Per Share Basic net income (loss) per common share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For the purposes of the diluted net income (loss) per share calculation, the convertible preferred stock, common stock options, RSU awards, performance stock awards, convertible preferred stock warrants, common stock warrants, convertible notes, earnout shares, and Sponsor Vesting Shares (as defined below) are considered to be potentially dilutive securities. Basic and diluted net income (loss) per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. All series of the Company’s convertible preferred stock are considered to be participating securities because, in addition to cumulative dividends, all holders are entitled to receive a non-cumulative dividend on a pari passu
Reclassifications	Reclassifications Certain amounts on the balance sheet in prior periods have been condensed to conform with the current presentation for the six months ended June 30, 2023.
Segment Reporting	Segment Reporting
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In October 2021, the FASB issued ASU 2021-08, Business Combinations (“Topic 805”), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . This update improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) recognition of an acquired contract liability; and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. Specifically, the update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers . The amendments in this update are effective for the Company in the fiscal year beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted the new standard as of January 1, 2023. The adoption of the standard had no material impact on the Company’s financial results. In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (“Topic 815”) (“ASU 2022-01”). This update clarifies the guidance in Topic 815 on fair value hedge accounting of interest rate risk for portfolios and financial assets. Among other things, the amended guidance established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible and renamed that method the “portfolio layer” method. ASU 2022-01 is effective January 1, 2023. The Company adopted the new standard as of January 1, 2023. The adoption of the standard had no material impact on the Company’s financial results. In September 2022, the FASB issued ASU 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50) . These amendments in this update improves financial reporting by requiring new disclosures about programs thereby allowing financial statement users to better consider the effect of the programs on the Company’s working capital, liquidity and cash flows over time. The amendments in this update are effective for the Company in the fiscal year beginning after December 15, 2022, including interim periods within that fiscal year. The Company adopted the new standard as of January 1, 2023. The adoption of the standard had no material impact on the Company’s financial results. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions , which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. This guidance also requires certain disclosures for equity securities subject to contractual sale restrictions. The new guidance is required to be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. This guidance is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of Cash, Cash Equivalents, and Restricted Cash	Cash, cash equivalents, and restricted cash consisted of the following (in thousands): June 30, 2023 December 31, 2022 Cash and cash equivalents $ 65,523 $ 107,858 Restricted cash 490 490 Total cash, cash equivalents, and restricted cash $ 66,013 $ 108,348
Schedule of Estimated Useful Lives of Assets	The estimated useful lives of assets are as follows: Computer and other equipment 3 years Pilot plant 5 years Machinery and equipment 5 years Leasehold improvements 1-5 years Plants and improvements 20-40 years

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Measured at Fair Value	The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows: Fair Value as of June 30, 2023 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash, cash equivalents and restricted cash $ 66,013 $ — $ — $ 66,013 Marketable securities — 152,170 — 152,170 Derivative asset — 160 — 160 Total fair value $ 66,013 $ 152,330 $ — $ 218,343 Liabilities: Assumed common stock warrants (Public) $ 17,869 $ — $ — $ 17,869 Assumed common stock warrants (Private Placement) — 8,380 — 8,380 Earnout liability — — 22,386 22,386 Derivative liability — 9 — 9 Total fair value $ 17,869 $ 8,389 $ 22,386 $ 48,644 Fair Value as of December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash, cash equivalents and restricted cash $ 108,348 $ — $ — $ 108,348 Marketable securities — 215,464 — 215,464 Total fair value $ 108,348 $ 215,464 $ — $ 323,812 Liabilities: Assumed common stock warrants (Public) $ 21,015 $ — $ — $ 21,015 Assumed common stock warrants (Private Placement) — 9,856 — 9,856 Earnout liability — — 42,533 42,533 Derivative liability — 344 — 344 Total fair value $ 21,015 $ 10,200 $ 42,533 $ 73,748
Schedule of Marketable Securities	The following table summarized the marketable securities by major security type as follows: As of June 30, 2023 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds $ 74,647 $ 54 $ (2,989) $ 71,712 Asset-backed securities 65,077 12 (3,169) 61,920 U.S. government and agency securities 18,884 — (677) 18,207 Foreign government and agency securities 375 — (44) 331 Total marketable securities $ 158,983 $ 66 $ (6,879) $ 152,170 As of December 31, 2022 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 17,568 $ 38 $ — $ 17,606 Corporate bonds 115,134 — (4,923) 110,211 Asset-backed securities 70,825 8 (3,885) 66,948 U.S. government and agency securities 19,308 — (917) 18,391 Foreign government and agency securities 375 — (37) 338 Municipal/provincial bonds and other 2,000 — (30) 1,970 Total marketable securities $ 225,210 $ 46 $ (9,792) $ 215,464
Schedule of Marketable Security Contractual Maturities	The contractual maturities of the investments classified as marketable securities are as follows: As of June 30, 2023 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Corporate bonds $ 55,613 $ 16,099 $ — $ 71,712 Asset-backed securities — 910 61,010 61,920 U.S. government and agency securities 7,851 7,538 2,818 18,207 Foreign government and agency securities — 331 — 331 Total marketable securities $ 63,464 $ 24,878 $ 63,828 $ 152,170 As of December 31, 2022 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Commercial paper $ 17,606 $ — $ — $ 17,606 Corporate bonds 74,797 35,414 — 110,211 Asset-backed securities 1,907 4,833 60,207 66,947 U.S. government and agency securities 7,719 7,480 3,192 18,391 Foreign government and agency securities — 338 — 338 Municipal/provincial bonds and other 1,971 — — 1,971 Total marketable securities $ 104,000 $ 48,065 $ 63,399 $ 215,464

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant, and equipment consisted of the following: (in thousands) June 30, 2023 December 31, 2022 Land $ 11,331 $ 11,358 Pilot plant 4,767 4,599 Lab equipment 2,820 2,526 Machinery and equipment 1,005 948 Computer and other equipment 1,180 598 Construction in process 205,061 138,847 Total 226,164 158,876 Less accumulated depreciation and amortization (5,357) (4,693) Total property, plant, and equipment, net $ 220,807 $ 154,183

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets consisted of the following: (in thousands) June 30, 2023 December 31, 2022 Patents $ 413 $ 404 Less accumulated amortization (271) (244) Total intangible assets $ 142 $ 160

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory balances consist of the following: (in thousands) June 30, 2023 December 31, 2022 Finished goods $ 331 $ — Raw materials 15 — Total $ 346 $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
Summary of Stock Option Activity	The following tables summarize stock option activity under the Stock Plans: Outstanding Options Weighted Weighted Average Balance as of December 31, 2022 6,471,062 $ 0.17 7.29 Granted — — Exercised (163,096) 0.14 Forfeited / canceled — — Balance as of March 31, 2023 6,307,966 $ 0.17 7.03 Granted — — Exercised (208,807) 0.15 Forfeited / canceled (794) 0.14 Balance as of June 30, 2023 6,098,365 $ 0.17 6.77 Vested and expected to vest at June 30, 2023 6,098,365
Schedule of RSU and Performance Award Activity	The following table summarizes the RSU award and performance-based stock award activity: Outstanding Weighted-average grant date fair value Unvested balance at December 31, 2022 6,371,950 $ 6.24 Granted - RSU awards 163,544 5.15 RSU awards vested and converted to shares (70,670) 5.39 Forfeited - RSU awards (50,212) 5.53 Forfeited - performance-based stock awards (35,625) 5.46 Unvested balance March 31, 2023 6,378,987 $ 6.22 Granted - RSU awards 387,841 4.14 RSU awards vested and converted to shares (50,693) 7.01 Forfeited - RSU awards (118,008) 6.01 Forfeited - performance-based stock awards (21,150) 5.56 Unvested balance June 30, 2023 6,576,977 $ 6.10 Expected to vest 4,414,827

Basic and Diluted Net Income _2

Basic and Diluted Net Income Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Summary of basic and diluted income per share	The following table sets forth the computation of basic and diluted net income (loss) per share: (In thousands, except for share and per share amounts) Three Months Ended Six Months Ended 2023 2022 2023 2022 Numerator: Net income (loss) attributable to common stockholders—Basic $ (6,464) $ 46,931 $ 3,305 $ 54,277 Net income (loss) attributable to common stockholders—Diluted $ (6,464) $ 46,931 $ 3,305 $ 54,277 Denominator: Weighted-average common shares outstanding—Basic (1) 139,265,248 137,141,655 139,154,557 136,985,440 Stock options — 4,889,299 3,730,144 5,010,955 RSU awards — 164,683 154,734 82,357 Weighted-average common shares outstanding—Diluted (1) 139,265,248 142,195,637 143,039,435 142,078,752 Net income (loss) per share—Basic $ (0.05) $ 0.34 $ 0.02 $ 0.40 Net income (loss) per share—Diluted $ (0.05) $ 0.33 $ 0.02 $ 0.38 (1) Excludes weighted-average Sponsor Vesting Shares subject to return of 4,500,000 shares as of June 30, 2023 and 2022.
Summary of Potentially Dilutive Securities for Common Stock	The following potentially dilutive securities for common stock were outstanding and excluded from diluted earnings per share as they are subject to performance or market conditions that were not achieved as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Options to purchase common stock 1,481,531 1,481,531 1,481,531 1,481,531 Performance-based stock awards 2,162,150 2,610,500 2,162,150 2,610,500 Earnout shares 25,000,000 25,000,000 25,000,000 25,000,000 Sponsor vesting shares 4,500,000 4,500,000 4,500,000 4,500,000 The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net income (loss) per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended Six Months Ended 2023 2022 2023 2022 Options to purchase common stock 4,616,840 — — — Warrants to purchase common stock 35,476,627 35,476,627 35,476,627 35,476,627 RSU awards 4,416,828 — — —

Risks and Liquidity - Narrative

Risks and Liquidity - Narrative (Detail) $ in Millions	Jun. 30, 2023 USD ($)
Risks And Liquidity [Abstract]
Proceeds for business combination	$ 217.7

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Detail) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2019 CAD ($)	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) plan segment $ / shares shares	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) shares	Sep. 27, 2019 USD ($)
Significant Accounting Policies [Line Items]
Escrow deposit fair value							$ 1,300,000
Escrow deposit		$ 300,000		$ 300,000		$ 300,000
Grants received		$ 100,000	$ 0	100,000	$ 0
Impairment of long lived assets				$ 0
Exercise price (in dollars per share) | $ / shares		$ 11.50		$ 11.50
Outstanding warrants (in shares) | shares		35,476,627		35,476,627		35,476,627
Percent of occurrence of a tender offer or exchange of our stockholders		50%		50%
Number of equity incentive plans (in plans) | plan				3
Number of operating segments (in segments) | segment				1
Total assets		$ 476,704,000		$ 476,704,000		$ 493,700,000
Plants and improvements
Significant Accounting Policies [Line Items]
Estimated useful lives		40 years		40 years
Foreign exchange contract
Significant Accounting Policies [Line Items]
Derivative, notional amount		$ 16,600,000		$ 16,600,000		21,200,000
Public Warrants
Significant Accounting Policies [Line Items]
Number of warrants assumed (in shares) | shares		24,149,960		24,149,960
Outstanding warrants (in shares) | shares		24,149,960		24,149,960
Private Placement Warrants
Significant Accounting Policies [Line Items]
Number of warrants assumed (in shares) | shares		11,326,667		11,326,667
Outstanding warrants (in shares) | shares		11,326,667		11,326,667
Maximum
Significant Accounting Policies [Line Items]
Payments due (in days)				90 days
Reimbursement for eligible expenditure	$ 1.8
Intangible assets, estimated useful lives		15 years		15 years
Maximum | Plants and improvements
Significant Accounting Policies [Line Items]
Estimated useful lives		40 years		40 years
Minimum
Significant Accounting Policies [Line Items]
Payments due (in days)				30 days
Intangible assets, estimated useful lives		7 years		7 years
Minimum | Plants and improvements
Significant Accounting Policies [Line Items]
Estimated useful lives		20 years		20 years
Outside United States
Significant Accounting Policies [Line Items]
Total assets		$ 179,900,000		$ 179,900,000		157,200,000
Standby Letters of Credit
Significant Accounting Policies [Line Items]
Letter of credit		$ 200,000		$ 200,000		$ 200,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash and cash equivalents	$ 65,523	$ 107,858
Restricted cash	490	490
Total cash, cash equivalents, and restricted cash	$ 66,013	$ 108,348	$ 79,546	$ 47,127

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)	Jun. 30, 2023
Computer and other equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Pilot plant
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Leasehold improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	1 year
Leasehold improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Plants and improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives	40 years
Plants and improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	20 years
Plants and improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	40 years

Revenue (Details)

Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenues	$ 6,898,000	$ 0	$ 8,602,000	$ 0

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Assets And Liabilities Measured At Fair Value (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Assets:
Marketable securities	$ 152,170	$ 215,464
Fair Value, Recurring
Assets:
Cash, cash equivalents and restricted cash	66,013	108,348
Marketable securities	152,170	215,464
Derivative asset	160
Total fair value	218,343	323,812
Liabilities:
Earnout liability	22,386	42,533
Derivative liability	9	344
Total fair value	48,644	73,748
Fair Value, Recurring | Level 1
Assets:
Cash, cash equivalents and restricted cash	66,013	108,348
Marketable securities	0	0
Derivative asset	0
Total fair value	66,013	108,348
Liabilities:
Earnout liability	0	0
Derivative liability	0	0
Total fair value	17,869	21,015
Fair Value, Recurring | Level 2
Assets:
Cash, cash equivalents and restricted cash	0	0
Marketable securities	152,170	215,464
Derivative asset	160
Total fair value	152,330	215,464
Liabilities:
Earnout liability	0	0
Derivative liability	9	344
Total fair value	8,389	10,200
Fair Value, Recurring | Level 3
Assets:
Cash, cash equivalents and restricted cash	0	0
Marketable securities	0	0
Derivative asset	0
Total fair value	0	0
Liabilities:
Earnout liability	22,386	42,533
Derivative liability	0	0
Total fair value	22,386	42,533
Assumed common stock warrants (Public) | Fair Value, Recurring
Liabilities:
Warrants or rights outstanding	17,869	21,015
Assumed common stock warrants (Public) | Fair Value, Recurring | Level 1
Liabilities:
Warrants or rights outstanding	17,869	21,015
Assumed common stock warrants (Public) | Fair Value, Recurring | Level 2
Liabilities:
Warrants or rights outstanding	0	0
Assumed common stock warrants (Public) | Fair Value, Recurring | Level 3
Liabilities:
Warrants or rights outstanding	0	0
Assumed common stock warrants (Private Placement) | Fair Value, Recurring
Liabilities:
Warrants or rights outstanding	8,380	9,856
Assumed common stock warrants (Private Placement) | Fair Value, Recurring | Level 1
Liabilities:
Warrants or rights outstanding	0	0
Assumed common stock warrants (Private Placement) | Fair Value, Recurring | Level 2
Liabilities:
Warrants or rights outstanding	8,380	9,856
Assumed common stock warrants (Private Placement) | Fair Value, Recurring | Level 3
Liabilities:
Warrants or rights outstanding	$ 0	$ 0

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Marketable Securities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 158,983	$ 225,210
Unrealized Gains	66	46
Unrealized Losses	(6,879)	(9,792)
Fair Value	152,170	215,464
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	74,647	115,134
Unrealized Gains	54	0
Unrealized Losses	(2,989)	(4,923)
Fair Value	71,712	110,211
Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	65,077	70,825
Unrealized Gains	12	8
Unrealized Losses	(3,169)	(3,885)
Fair Value	61,920	66,948
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	18,884	19,308
Unrealized Gains	0	0
Unrealized Losses	(677)	(917)
Fair Value	18,207	18,391
Foreign government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	375	375
Unrealized Gains	0	0
Unrealized Losses	(44)	(37)
Fair Value	$ 331	338
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost		17,568
Unrealized Gains		38
Unrealized Losses		0
Fair Value		17,606
Municipal/provincial bonds and other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost		2,000
Unrealized Gains		0
Unrealized Losses		(30)
Fair Value		$ 1,970

Fair Value Measurement - Narrat

Fair Value Measurement - Narrative (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Sales of marketable securities			$ 2,462,950,000	$ 1,647,787,000
Realized loss (gain) on marketable securities	$ (100,000)	$ 0	700,000	500,000
Aggregate fair value of marketable securities in unrealized loss position	137,800,000		137,800,000		$ 193,500,000
Gain in fair value of earnout liability	7,508,000	33,188,000	20,380,000	48,414,000
Foreign exchange contract
Class of Warrant or Right [Line Items]
Net (loss) gain on foreign currency derivative contracts	$ (300,000)	$ 1,400,000	$ 500,000	$ 600,000

Fair Value Measurement - Market

Fair Value Measurement - Marketable Security Contractual Maturities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year		$ 104,000
Mature after one year through two years		48,065
Mature over two years		63,399
Fair Value		215,464
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	$ 55,613	74,797
Mature after one year through two years	16,099	35,414
Mature over two years	0	0
Fair Value	71,712	110,211
Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	0	1,907
Mature after one year through two years	910	4,833
Mature over two years	61,010	60,207
Fair Value	61,920	66,947
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	7,851	7,719
Mature after one year through two years	7,538	7,480
Mature over two years	2,818	3,192
Fair Value	18,207	18,391
Foreign government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	0	0
Mature after one year through two years	331	338
Mature over two years	0	0
Fair Value	331	338
Municipal/provincial bonds and other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year		1,971
Mature after one year through two years		0
Mature over two years		0
Fair Value		1,971
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year		17,606
Mature after one year through two years		0
Mature over two years		0
Fair Value		$ 17,606
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	63,464
Mature after one year through two years	24,878
Mature over two years	63,828
Fair Value	$ 152,170

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total	$ 226,164	$ 158,876
Less accumulated depreciation and amortization	(5,357)	(4,693)
Total property, plant, and equipment, net	220,807	154,183
Land
Property, Plant and Equipment [Line Items]
Total	11,331	11,358
Pilot plant
Property, Plant and Equipment [Line Items]
Total	4,767	4,599
Lab equipment
Property, Plant and Equipment [Line Items]
Total	2,820	2,526
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total	1,005	948
Computer and other equipment
Property, Plant and Equipment [Line Items]
Total	1,180	598
Construction in process
Property, Plant and Equipment [Line Items]
Total	$ 205,061	$ 138,847

Property, Plant and Equipment_2

Property, Plant and Equipment - Narrative (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0.3	$ 0.1	$ 0.6	$ 0.3
Capitalized interest cost	1.4		1.4		$ 1.1
Capitalized stock-based compensation	3.2		3.2		1.9
Cumulative translation adjustment	$ (3.3)		$ (3.3)		$ 3

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 413	$ 404
Less accumulated amortization	(271)	(244)
Intangible assets, net	$ 142	$ 160

Intangible Assets - Narrative (

Intangible Assets - Narrative (Detail)	6 Months Ended
	Jun. 30, 2023
Patents
Finite-Lived Intangible Assets [Line Items]
Intangible assets weighted average useful life	3 years 10 months 24 days

Consortium Agreement - Narrativ

Consortium Agreement - Narrative (Detail)	1 Months Ended		3 Months Ended		6 Months Ended
	Aug. 31, 2018 USD ($) investors	Dec. 31, 2016 USD ($) investors	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Company received amount from agreement		$ 500,000
Invested amount for research and development	$ 1,500,000
Other income			$ 0	$ 0	$ 0	$ 0
Consortium Agreement | Legacy Origin Series C Investor
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Company received amount from agreement					$ 0
Consortium Agreement | Legacy Origin Series B Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of investors | investors	2	2

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 331	$ 0
Raw materials	15	0
Total	$ 346	$ 0

Notes Payable - Narrative (Deta

Notes Payable - Narrative (Detail) $ in Thousands		1 Months Ended		6 Months Ended
	Aug. 01, 2022 USD ($)	May 31, 2019 USD ($) installment	Nov. 30, 2016 USD ($)	Jun. 30, 2023 USD ($) agreement	Dec. 31, 2022 USD ($)
Debt Disclosure [Line Items]
Number of offtake supply agreements (in agreements) | agreement				8
Number of offtake supply agreements with same customer (in agreements) | agreement				2
Note principal outstanding				$ 5,189	$ 5,847
Promissory Note
Debt Disclosure [Line Items]
Prepayment from stockholder			$ 5,000
Debt instrument, increase, accrued interest		$ 200
Number of installments (in installments) | installment		3
Long-term debt, maturity, year two	$ 2,700
Long-term debt, maturity, year three	1,900
Long-term debt, maturity, year four	$ 1,800
Accrued interest rate	3.50%
Note principal outstanding				5,200	5,200
Accrued interest				$ 700	$ 600
Initial term of offtake supply agreement				10 years
Promissory Note | Legacy stockholder note
Debt Disclosure [Line Items]
Principal amount	$ 5,200

Other Liabilities, Long-term -

Other Liabilities, Long-term - Narrative (Detail) $ in Millions	1 Months Ended		6 Months Ended	12 Months Ended
	Sep. 30, 2019 USD ($) installment	Nov. 30, 2016 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Other Liabilities [Line Items]
Other long-term debt		$ 5
Number of prepayment installments (in installments) | installment	2
Affiliated entity | Stockholder
Other Liabilities [Line Items]
Other long-term debt			$ 5.1	$ 5.1
Repayment period under prepayment agreement		5 years
Amount of repayment under prepayment agreement		$ 7.5
Repayment percentage of prepayment agreement amount		150%
Loan facility interest rate			5.31%
Loan facility term			5 years
Debt instrument accrued interest			$ 0.4	0.3
Affiliated entity | LIBOR | Stockholder
Other Liabilities [Line Items]
Loan facility interest rate			0.25%
Prepayment agreement
Other Liabilities [Line Items]
Other long-term debt	$ 5		$ 2.5	$ 2.5
Percentage of prepayment applied against future purchases	100%
Period of customer capacity reservation	10 years
Prepayment agreement | Installment 1
Other Liabilities [Line Items]
Debt instrument, periodic payment	$ 2.5
Prepayment agreement | Installment 2
Other Liabilities [Line Items]
Debt instrument, periodic payment	$ 2.5
Period of payment of prepayment agreement	30 days

Earnout Liability - Narrative (

Earnout Liability - Narrative (Detail) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Business Acquisition, Contingent Consideration [Line Items]
Post triggering event period			10 days
Earnout shares of common stock outstanding (in shares) | shares	25,000,000		25,000,000
Sponsor vesting shares of common stock outstanding (in shares) | shares	4,500,000		4,500,000
Gain in fair value of earnout liability | $	$ 7,508	$ 33,188	$ 20,380	$ 48,414
Earnout liability
Business Acquisition, Contingent Consideration [Line Items]
Earnout liability | $	22,400		22,400		$ 42,500
Gain in fair value of earnout liability | $	$ 7,500	$ 33,200	$ 20,400	$ 48,400
Earnout liability | Expected dividend rate
Business Acquisition, Contingent Consideration [Line Items]
Measurement input	0		0
Earnout liability | Price volatility
Business Acquisition, Contingent Consideration [Line Items]
Measurement input	0.68		0.68
Earnout liability | Risk free interest rate
Business Acquisition, Contingent Consideration [Line Items]
Measurement input	0.0440		0.0440
Earnout liability | Share trigger price 1
Business Acquisition, Contingent Consideration [Line Items]
Post triggering event period			10 days
Share price (in dollars per share) | $ / shares	$ 15		$ 15
Period from businees combination closing date stock price trigger			3 years
Earnout liability | Share trigger price 2
Business Acquisition, Contingent Consideration [Line Items]
Post triggering event period			10 days
Share price (in dollars per share) | $ / shares	20		$ 20
Period from businees combination closing date stock price trigger			4 years
Earnout liability | Share trigger price 3
Business Acquisition, Contingent Consideration [Line Items]
Post triggering event period			10 days
Share price (in dollars per share) | $ / shares	$ 25		$ 25
Period from businees combination closing date stock price trigger			5 years

Canadian Government Research _2

Canadian Government Research and Development Program Liability - Narrative (Detail) $ in Millions, $ in Millions	1 Months Ended
	Apr. 30, 2019 CAD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Research and Development [Abstract]
Lesser eligible costs percentage	18.48%
Lesser eligible costs	$ 23
Funding repayment period	15 years
Repayment ratio compared to actual funding received	1.25
Funding reduction percentage	50%
Minimum costs of commercial plants	$ 500
Commercial plants constructed and operational period	30 months
Funding liability		$ 7.3	$ 7.2

Assumed Common Stock Warrants -

Assumed Common Stock Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Number of warrants or rights outstanding (in shares)	35,476,627		35,476,627		35,476,627
Assumed common stock warrants liability	$ 26,249		$ 26,249		$ 30,872
Change in fair value of gain assumed warrants	$ (2,100)	$ 18,800	$ 4,600	$ 17,000
Share trigger price 1
Class of Warrant or Right [Line Items]
Class of warrants redemption price per unit (in dollars per share)	$ 0.01		$ 0.01
Class of warrants redemption notice period			30 days
Warrant instrument redemption threshold consecutive trading days			20 days
Trading period			30 days
Public Warrants
Class of Warrant or Right [Line Items]
Warrants issued during the period (in shares)			24,149,960
Number of common stock shares converted (in shares)	1		1
Share price (in dollars per share)	$ 11.50		$ 11.50
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrants issued during the period (in shares)			11,326,667
Number of common stock shares converted (in shares)	1		1
Share price (in dollars per share)	$ 11.50		$ 11.50
Private Warrant
Class of Warrant or Right [Line Items]
Share price (in dollars per share)	12		$ 12
Warrant instrument redemption threshold consecutive trading days			20 days
Trading period			30 days
Minimum lock In period required for warrant exercise from the date of business combination			365 days
Number of days for a particular event to get over for determining trading period			150 days
Common Class A | Minimum
Class of Warrant or Right [Line Items]
Share redemption trigger price per share (in dollars per share)	10		$ 10
Common Class A | Maximum
Class of Warrant or Right [Line Items]
Share redemption trigger price per share (in dollars per share)	18		18
Common Class A | Share trigger price 1
Class of Warrant or Right [Line Items]
Share redemption trigger price per share (in dollars per share)	$ 18		$ 18

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Detail) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2021	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2021	Jun. 30, 2021
Class of Stock [Line Items]
Common stock, shares authorized (in shares)	1,000,000,000				1,000,000,000		1,000,000,000
Common stock, par value (in dollars per share)	$ 0.0001				$ 0.0001		$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000				10,000,000		10,000,000
Common stock, voting rights					one
Common stock, shares outstanding (in shares)	143,498,724				143,498,724		143,034,225
Sponsor vesting shares outstanding (in shares)	4,500,000				4,500,000		4,500,000
Stock options available for grant (in shares)	15,694,899				15,694,899		15,728,837
Stock options, exercisable (in shares)	3,651,658				3,651,658		3,588,523
Total intrinsic value of options exercised	$ 900,000		$ 5,000,000		$ 1,800,000	$ 5,700,000
Stock option, aggregate intrinsic value	24,900,000				24,900,000		$ 28,700,000
Cost not yet recognized	3,200,000				$ 3,200,000		$ 4,700,000
Stock compensation not yet recognized, vesting period					1 year 2 months 12 days		1 year 8 months 12 days
Stock-based compensation					$ 4,651,000	2,573,000
Stock compensation not yet recognized	22,700,000				22,700,000
General and administrative expense
Class of Stock [Line Items]
Stock-based compensation	1,500,000		1,300,000		3,000,000	2,000,000
Research and development expense
Class of Stock [Line Items]
Stock-based compensation	700,000		300,000		$ 1,500,000	500,000
Performance and market based awards
Class of Stock [Line Items]
Stock options issued during the period (in shares)								2,920,732
Stock options, vested (in shares)				529,119
Performance and market based awards | First vesting
Class of Stock [Line Items]
Stock option plan, vesting percentage				2.083%
Stock options, outstanding (in shares)				529,119
Performance and market based awards | Second vesting
Class of Stock [Line Items]
Stock options, outstanding (in shares)										2,391,613
RSU awards
Class of Stock [Line Items]
Option vesting period					2 years 3 months 18 days
Total intrinsic value of options exercised	$ 200,000		$ 700,000		$ 600,000	700,000
Vested (in shares)	50,693	70,670
Options to purchase common stock
Class of Stock [Line Items]
Option vesting period					1 year 2 months 12 days
Stock options issued during the period (in shares)	0	0			0
Performance Shares
Class of Stock [Line Items]
Unvested outstanding (in shares)	1,976,725				1,976,725
Employee Stock Purchase Plan | Employee Stock
Class of Stock [Line Items]
Purchase price of common stock					85%
Number of shares authorized (in shares)	5,639,944				5,639,944		3,722,490		1,846,710
Evergreen shares reserve feature period					10 years
Increase in shares authorized					1%
Increase in number of shares of authorized common stock (in shares)					3,693,420
Number of additional shares authorized (in shares)					1,917,454
Stock Plans
Class of Stock [Line Items]
Stock option plan, exercisable period					4 years
Stock Plans | RSU awards
Class of Stock [Line Items]
Option vesting period					3 years
Requisite service period					3 years
Stock Plans | RSU awards | Tranche one
Class of Stock [Line Items]
Stock option plan, vesting percentage					33.30%
Stock Plans | RSU awards | Tranche two
Class of Stock [Line Items]
Stock option plan, vesting percentage					33.30%
Stock Plans | RSU awards | Tranche three
Class of Stock [Line Items]
Stock option plan, vesting percentage					33.30%
Stock Plans | Employee Stock
Class of Stock [Line Items]
Common stock, shares reserved (in shares)	28,761,816				28,761,816		27,846,011
Stock Plans | Performance Shares | Minimum
Class of Stock [Line Items]
Stock option plan, vesting percentage					0%
Stock Plans | Performance Shares | Maximum
Class of Stock [Line Items]
Stock option plan, vesting percentage					300%
Stock Plans | Share-based payment arrangement, nonemployee
Class of Stock [Line Items]
Stock option plan, exercisable period					10 years
Stock Plans | One year from the vesting commencement date
Class of Stock [Line Items]
Stock option plan, vesting percentage					25%
Option vesting period					1 year
Stock Plans | More than one year from vesting commencement date
Class of Stock [Line Items]
Stock option plan, vesting percentage					2.778%
2021 Equity Incentive Plan | RSU awards
Class of Stock [Line Items]
Stock compensation not yet recognized, vesting period					3 years
Cost not yet recognized, excluding options	$ 19,400,000				$ 19,400,000
2021 Equity Incentive Plan | Employee Stock
Class of Stock [Line Items]
Number of shares authorized (in shares)							18,467,109
Evergreen shares reserve feature period					10 years
Increase in shares authorized					5%
Number of additional shares authorized (in shares)					915,805
Maximum percentage of share reserve, outstanding diluted stock					15%
2021 Equity Incentive Plan | Performance Shares
Class of Stock [Line Items]
Share-based payment arrangement expense					$ 0	$ 0
Vested (in shares)					0	0
Common Stock
Class of Stock [Line Items]
Common stock, shares authorized (in shares)	1,010,000,000				1,010,000,000		1,010,000,000
Common stock, par value (in dollars per share)	$ 0.0001				$ 0.0001		$ 0.0001
Warrants issued (in shares)					1,000,000,000		1,000,000,000
Common stock, shares outstanding (in shares)	143,498,724				143,498,724		143,034,225

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity (Detail) - $ / shares	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Weighted Average Exercise Price
Ending balance (in dollars per share)	$ 0.17		$ 0.17
Options to purchase common stock
Outstanding Options
Beginning balance (in shares)	6,307,966	6,471,062	6,471,062
Granted (in shares)	0	0	0
Exercised (in shares)	(208,807)	(163,096)
Forfeited / canceled (in shares)	(794)	0
Ending balance (in shares)	6,098,365	6,307,966	6,098,365	6,471,062
Vested and expected to vest (in shares)	6,098,365		6,098,365
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 0.17	$ 0.17	$ 0.17
Granted (in dollars per share)	0	0
Exercised (in dollars per share)	0.15	0.14
Forfeited / canceled (in dollars per share)	$ 0.14	0
Ending balance (in dollars per share)		$ 0.17		$ 0.17
Weighted Average Remaining Contractual Life (in years)
Weighted Average Remaining Contractual Life (in years)	6 years 9 months 7 days	7 years 10 days		7 years 3 months 14 days

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of RSU and Performance Award Activity (Detail) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023
RSUs and performance shares
Outstanding
Beginning unvested balance (in shares)	6,378,987	6,371,950	6,371,950
Ending unvested balance (in shares)	6,576,977	6,378,987	6,576,977
Expected to vest (in shares)	4,414,827		4,414,827
Weighted-average grant date fair value
Beginning unvested balance (in dollars per share)	$ 6.22	$ 6.24	$ 6.24
Ending unvested balance (in dollars per share)	$ 6.10	$ 6.22	$ 6.10
RSU awards
Outstanding
Granted (in shares)	387,841	163,544
Vested (in shares)	(50,693)	(70,670)
Forfeited (in shares)	(118,008)	(50,212)
Weighted-average grant date fair value
Granted (in dollars per share)	$ 4.14	$ 5.15
Vested (in dollars per share)	7.01	5.39
Forfeited (in dollars per share)	$ 6.01	$ 5.53
Performance-based stock awards
Outstanding
Forfeited (in shares)	(21,150)	(35,625)
Ending unvested balance (in shares)	1,976,725		1,976,725
Weighted-average grant date fair value
Forfeited (in dollars per share)	$ 5.56	$ 5.46

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income tax provision	$ 129	$ 0	$ 129	$ 0
Effective income tax rate	(1.68%)	0%	3.29%	0%

Leases - Narrative (Details)

Leases - Narrative (Details)	Jun. 30, 2023
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	8 years

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Detail) € in Millions

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Jul. 31, 2017 USD ($)

Dec. 31, 2016 USD ($)

Nov. 30, 2016 USD ($)

Apr. 30, 2023 USD ($)

May 31, 2018 USD ($)

Sep. 30, 2011 USD ($)

Jun. 30, 2011 USD ($)

Jun. 30, 2023 USD ($)

Mar. 31, 2023 EUR (€)

Jun. 30, 2022 USD ($)

Jun. 30, 2023 USD ($)

Jun. 30, 2022 USD ($)

Dec. 31, 2022 EUR (€)

Other Commitments [Line Items]

Take-Or-Pay basis, term

5 years

Take-Or-Pay basis, contract cost

$ 35,000,000

License payment, royalty payment

$ 0

$ 0

$ 0

$ 0

Operating and Maintenance Agreement

Other Commitments [Line Items]

Service agreement, periods

5 years

Operating and maintenance agreements, automatic extension periods

1 year

Capitalized property, plant and equipment

0

400,000

200,000

500,000

Operating and Maintenance Agreement | Minimum

Other Commitments [Line Items]

Operating and maintenance agreements, fixed payments per year

$ 400,000

Nonexclusive Patents Llicense Agreement

Other Commitments [Line Items]

License agreement amount | €

€ 5

Additional payments for license agreement | €

€ 7.5

Percentage of net sales

0.40%

Patent License Agreement

Other Commitments [Line Items]

License agreement amount

$ 100,000

$ 500,000

Royalty payment per year (less than)

$ 100,000

Royalty payment, cumulative amount

500,000

$ 10,000,000

Upfront license fee royalty and a variable royalty, aggregate cap per facility

$ 10,000,000

License payment, royalty payment

$ 0

$ 0

$ 0

$ 0

Patent License Agreement | Minimum

Other Commitments [Line Items]

Royalty payment per year (less than)

$ 100,000

Patent License Agreement | Maximum

Other Commitments [Line Items]

Royalty payment per year (less than)

$ 100,000

Royalty payment, cumulative amount

$ 1,000,000

$ 2,000,000

Basic and Diluted Net Income _3

Basic and Diluted Net Income Per Share - Summary of Basic And Diluted Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net income (loss) attributable to common stockholders—Basic	$ (6,464)	$ 46,931	$ 3,305	$ 54,277
Net income (loss) attributable to common stockholders—Diluted	$ (6,464)	$ 46,931	$ 3,305	$ 54,277
Denominator:
Weighted-average common shares outstanding—Basic (in shares)	139,265,248	137,141,655	139,154,557	136,985,440
Weighted-average common shares outstanding—Diluted (in shares)	139,265,248	142,195,637	143,039,435	142,078,752
Net income (loss) per share —Basic (in dollars per share)	$ (0.05)	$ 0.34	$ 0.02	$ 0.40
Net income (loss) per share—Diluted (in dollars per share)	$ (0.05)	$ 0.33	$ 0.02	$ 0.38
Stock options
Denominator:
Dilutive share based payment arrangements (in shares)	0	4,889,299	3,730,144	5,010,955
RSU awards
Denominator:
Dilutive share based payment arrangements (in shares)	0	164,683	154,734	82,357

Basic and Diluted Net Income _4

Basic and Diluted Net Income Per Share - Narrative (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Weighted-average sponsor vesting shares subject to return (in shares)	4,500,000	4,500,000	4,500,000	4,500,000

Basic and Diluted Net Income _5

Basic and Diluted Net Income Per Share - Summary of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	4,616,840	0	0	0
Options to purchase common stock | Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,481,531	1,481,531	1,481,531	1,481,531
Performance-based stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	2,162,150	2,610,500	2,162,150	2,610,500
Earnout shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	25,000,000	25,000,000	25,000,000	25,000,000
Sponsor vesting shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	4,500,000	4,500,000	4,500,000	4,500,000
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	35,476,627	35,476,627	35,476,627	35,476,627
RSU awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	4,416,828	0	0	0